var title_f16_33_16912="Deep partial thickness burn";
var content_f16_33_16912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deep partial-thickness burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Easily unroofed blisters that do not blanch with pressure and have a waxy appearance typify deep partial-thickness burns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16912=[""].join("\n");
var outline_f16_33_16912=null;
var title_f16_33_16913="High arched palate";
var content_f16_33_16913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High arched palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palate with a high and narrow maxillary arch in a patient with obstructive sleep apnea. The tongue cannot fit into the narrow palate. Therefore, the tongue tends to move backward when the patient is supine, blocking the airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rafael Pelayo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16913=[""].join("\n");
var outline_f16_33_16913=null;
var title_f16_33_16914="Bladder exstrophy female";
var content_f16_33_16914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Bladder exstrophy (female)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dr. Joseph G Borer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16914=[""].join("\n");
var outline_f16_33_16914=null;
var title_f16_33_16915="Multivisceral transplant";
var content_f16_33_16915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Multivisceral transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Khan FA, Tzakis AG. Intestinal and multivisceral transplantation. In: Transplantation, Ginnis LC, Cosmi AB, and Morris PJ (Eds), Blackwell, Malden 1999. p.422.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16915=[""].join("\n");
var outline_f16_33_16915=null;
var title_f16_33_16916="Fluoroscopic view of double balloon enteroscopy";
var content_f16_33_16916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluoroscopic view of double balloon enteroscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image showing the concentric circles that are formed during double balloon enteroscopy as loops are reduced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hiroto Kita, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16916=[""].join("\n");
var outline_f16_33_16916=null;
var title_f16_33_16917="Overview of gastrointestinal peptides in health and disease";
var content_f16_33_16917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of gastrointestinal peptides in health and disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16917/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16917/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16917/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16917/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16917/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16917/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/33/16917/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal (GI) tract has been called the largest endocrine organ because of its complement of endocrine cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These cells produce a variety of chemical transmitters that are involved in gastrointestinal motility, secretion, absorption, growth, and development. Many of the peptides in the GI tract are also found in the enteric nervous system and the central nervous system.",
"   </p>",
"   <p>",
"    Gastrointestinal peptides have been classified into \"families\" according to their primary structure (",
"    <a class=\"graphic graphic_table graphicRef52723 \" href=\"UTD.htm?28/41/29340\">",
"     table 1",
"    </a>",
"    ). Conservation of amino acid sequence among peptides suggests a common biosynthetic origin. An overview of gastrointestinal peptides in health and disease will be discussed here. The regulation and functions of the individual peptides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=see_link\">",
"     \"Synthesis, secretion, and regulation of gastrointestinal peptides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link\">",
"     \"Physiology of gastrin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=see_link\">",
"     \"Pancreatic polypeptide, peptide YY, and neuropeptide Y\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=see_link\">",
"     \"Insulin action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=see_link\">",
"     \"Physiology of somatostatin and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most GI peptides were discovered based upon their biologic function, and bioassays were developed to quantify peptides in serum and tissue extracts. With the introduction of the radioimmunoassay (RIA) by Yalow and Berson in the 1960s, direct measurement of serum hormone concentrations could be obtained with high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/3\">",
"     3",
"    </a>",
"    ]. The RIA has been one of the most useful methods for establishing the physiology of gut peptides; it has also accelerated the pace of peptide hormone discovery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/4\">",
"     4",
"    </a>",
"    ]. With advances in molecular biology it has been possible to over-express or eliminate hormone secretion in transgenic or knockout animals, respectively. These tools have been extremely valuable in deciphering the function of GI peptides.",
"   </p>",
"   <p>",
"    The cells which produce gastrointestinal peptides are dispersed throughout the GI tract. Regulatory peptides are found in the esophagus, stomach, small and large bowel, and the pancreas. The endocrine producing cells of the GI tract, although diffuse, are localized to general regions (",
"    <a class=\"graphic graphic_table graphicRef65917 \" href=\"UTD.htm?20/18/20780\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/5\">",
"     5",
"    </a>",
"    ]. This regional specificity is probably related to the physiologic action of each substance. At least equally important is receptor location since all GI peptides signal through membrane receptors on target cells.",
"   </p>",
"   <p>",
"    Although GI peptides are typically thought of as hormones, not all peptides act via the traditional endocrine pathway by which they are secreted into the blood stream and act at a distant site. GI peptides can act (",
"    <a class=\"graphic graphic_figure graphicRef77856 \" href=\"UTD.htm?30/23/31091\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      On the same cells from which they are released (autocrine)",
"     </li>",
"     <li>",
"      On neighboring cells (paracrine)",
"     </li>",
"     <li>",
"      Via classic endocrine mechanisms",
"     </li>",
"     <li>",
"      On cells following their release from nerves (neurocrine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus far, only gastrin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    , and cholecystokinin have been proven to act as true hormones, although multiple other peptides may function in this manner (",
"    <a class=\"graphic graphic_table graphicRef64495 \" href=\"UTD.htm?4/28/4556\">",
"     table 3",
"    </a>",
"    ). In order to be designated a hormone, a substance should fulfill the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Be released by physiologic stimuli",
"     </li>",
"     <li>",
"      Produce its physiologic response when administered intravenously",
"     </li>",
"     <li>",
"      Circulate in vivo in concentrations capable of producing the response",
"     </li>",
"     <li>",
"      Have its actions blocked by specific antagonists or antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regulation of GI peptide secretion is necessary for normal bowel function, including nutrient assimilation and homeostasis. Alterations in either hormone secretion or action can have deleterious effects. Some of the most notable settings in which adverse effects can occur are overproduction of peptides by GI tumors (eg, gastrinoma, VIPoma), loss of regulation caused by medication-induced hypersecretion, and receptor signaling errors as occurs in toxin-induced diarrhea.",
"   </p>",
"   <p>",
"    Any enteroendocrine cell within the GI tract can serve as a nidus for hyperplasia or neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/6\">",
"     6",
"    </a>",
"    ]. Although these tumors are rare, their secreted hormones often produce clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef71093 \" href=\"UTD.htm?25/37/26203\">",
"     table 4",
"    </a>",
"    ). Most gut endocrine tumors elaborate several secretory products but one hormone usually predominates. The clinical findings are determined by the amount and type of peptide secreted. The most common clinical entity associated with GI hormone hypersecretion is gastrinoma (Zollinger-Ellison syndrome). Gastrin has served as the prototype for discussions on GI hormones for a number of reasons. First, gastrin was one of the original hormones for which a reliable assay was developed for measuring serum levels. Second, its physiologic effect is easy to measure (gastric secretion). Third, excess secretion causes a dramatic and easily diagnosed clinical disease, peptic ulcer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most peptide hormones transduce their information through G protein-coupled receptors (GPCRs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    .) In certain circumstances, defects in receptor signaling or coupling can produce disease in the absence of excess hormone production. As an example, Vibrio cholerae toxin covalently modifies the alpha-subunit of the stimulatory G protein in enterocytes. This activates the signaling pathway and stimulates intestinal secretion, resulting in voluminous watery diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the physiology of GI peptides has led to novel therapeutic uses (",
"    <a class=\"graphic graphic_table graphicRef68963 \" href=\"UTD.htm?12/62/13292\">",
"     table 5",
"    </a>",
"    ). The most widely used is the somatostatin analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . Somatostatin has a short serum half-life while octreotide is resistant to degradation and remains biologically active for hours. Octreotide has been used for the treatment of endocrine tumors, certain diarrheal states, variceal hemorrhage, GI hormone-secreting tumors (particularly VIPoma), and GI tumor diagnostic testing (somatostatin receptor scintigraphy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Developing GI hormones as pharmaceutical agents has been difficult since, as peptides, they are inactivated by gastric acid and digested when given orally [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/8\">",
"     8",
"    </a>",
"    ]. Other routes of administration such as subcutaneous, intramuscular, and intravenous injection have limited use. Nevertheless, considerable progress has been made in the development of drugs targeted at specific GI hormone receptors. Drugs under development include small molecule cholecystokinin receptor agonists, peptide YY analogues such as PYY(3-36) for the treatment of obesity, and GI hormones that possess incretin activity (ie, cause increased release of insulin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35638?source=see_link\">",
"     \"Physiology of cholecystokinin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=see_link\">",
"     \"Pancreatic polypeptide, peptide YY, and neuropeptide Y\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since GI hormones have been found to play a role in energy homeostasis, strategies are being developed to modulate circulating hormone concentration or target specific gut hormone receptors as potential therapies for obesity. Some of these include anorectic hormones (PYY and oxyntomodulin), amylin, and the orexigenic hormone ghrelin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H37#H37\">",
"     \"Drug therapy of obesity\", section on 'Experimental drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GI hormones that possess incretin activity (eg, glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide-1 [GLP-1]) are potentially useful for treatment of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/10\">",
"     10",
"    </a>",
"    ]. Peptide analogs and small molecule agonists are under development. These drugs would be expected to enhance glucose-stimulated insulin release, although they may improve glucose tolerance through other actions on the gastrointestinal tract such as delaying gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=see_link\">",
"     \"Amylin analogs for the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One incretin mimetic is a synthetic form of Gila monster venom, exendin-4 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ), which is structurally similar to human GLP-1 but is less susceptible to enzymatic degradation. Exenatide, which is administered by injection, lowers circulating glucose levels. It has been shown to effectively reduce glycated hemoglobin (HbA1c) in diabetics undergoing long-term treatment, and the drug (exenatide) is currently approved in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following their natural secretion, both GIP and GLP-1 are subject to rapid degradation by the enzyme dipeptidyl peptidase IV (DP IV). Thus, another strategy for increasing the bioactivity of these hormones is to inhibit the proteolytic action of DP IV. The DP IV inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    has been approved in the United States and is believed to improve glycemic control in diabetics by inhibiting the degradation of both GIP and GLP-1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucagon-like peptide-2 analogs are being developed for treatment of short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16917/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In the future, technological developments such as nasal sprays, transdermal agents, and acid",
"    <span class=\"nowrap\">",
"     resistant/coated",
"    </span>",
"    preparations may expand the possibilities for GI peptide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365248287\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gastrointestinal (GI) tract has the largest complement of endocrine cells that produce a variety of chemical transmitters involved in gastrointestinal motility, secretion, absorption, growth, and development. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cells which produce gastrointestinal peptides are dispersed throughout the GI tract. The endocrine producing cells of the GI tract, although diffuse, are localized to general regions related to the physiologic action of each substance. Regulatory peptides are found in the esophagus, stomach, small and large bowel, and the pancreas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of GI peptide secretion is necessary for normal bowel function, including nutrient assimilation and homeostasis. Alterations in either hormone secretion or action can have deleterious effects. Adverse effects can occur due to overproduction of peptides by GI tumors (eg, gastrinoma, VIPoma), loss of regulation caused by medication-induced hypersecretion, and receptor signaling errors as occurs in toxin-induced diarrhea. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Understanding the physiology of GI peptides has led to novel therapeutic uses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely used GI peptide is the somatostatin analogue,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      . Octreotide has been used for the treatment of endocrine tumors, certain diarrheal states, variceal hemorrhage, GI hormone-secreting tumors (particularly VIPoma), and GI tumor diagnostic testing (somatostatin receptor scintigraphy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GI hormones that cause increased release of insulin (eg, glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide-1 [GLP-1]) are potentially useful for treatment of diabetes mellitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An incretin mimetic, exendin-4 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      ), a synthetic form of Gila monster venom, is structurally similar to human GLP-1 but is less susceptible to enzymatic degradation. Exenatide has been shown to effectively reduce glycated hemoglobin (HbA1c) in diabetics undergoing long-term treatment.",
"     </li>",
"     <li>",
"      The DP IV inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      , is believed to improve glycemic control in diabetics by inhibiting the degradation of both GIP and GLP-1. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs under development include anorectic hormones (PYY and oxyntomodulin), amylin, and the orexigenic hormone ghrelin for the treatment of obesity and glucagon-like peptide-2 analogs for treatment of short bowel syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gut Peptides, Walsh JH, Dockray GJ (Eds), Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     Physiology of the Gastrointestinal Tract, 4th ed, Johnson LR (Ed), Elsevier Academic Press, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/3\">",
"      Grossman MI. Neural and hormonal regulation of gastrointestinal function: an overview. Annu Rev Physiol 1979; 41:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/4\">",
"      Shulkes A. Gastrointestinal hormones: from basic science to a clinical perspective. Aust N Z J Surg 1990; 60:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/5\">",
"      Solcia E, Fiocca R, Rindi G, et al. The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 1993; 22:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/6\">",
"      Longnecker DS. Hormones and receptors in gastrointestinal malignancies. Digestion 1990; 46 Suppl 2:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/7\">",
"      Gill DM, Woolkalis MJ. Cholera toxin-catalyzed [32P]ADP-ribosylation of proteins. Methods Enzymol 1991; 195:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/8\">",
"      Redfern JS, O'Dorisio TM. Therapeutic uses of gastrointestinal peptides. Endocrinol Metab Clin North Am 1993; 22:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/9\">",
"      Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010; 316:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/10\">",
"      Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/11\">",
"      Brubaker PL. Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 2007; 18:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/12\">",
"      Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/13\">",
"      Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16917/abstract/14\">",
"      Yazbeck R. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Curr Opin Mol Ther 2010; 12:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2534 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16917=[""].join("\n");
var outline_f16_33_16917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365248287\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365248287\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/23/31091\" title=\"figure 1\">",
"      GI peptides and cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/41/29340\" title=\"table 1\">",
"      GI peptide families",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/18/20780\" title=\"table 2\">",
"      Gastroenteropancreatic endocrine cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/28/4556\" title=\"table 3\">",
"      GI peptide modes of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/37/26203\" title=\"table 4\">",
"      Sx GI endocrine neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/62/13292\" title=\"table 5\">",
"      Gastrointestinal peptides used in clinical practice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=related_link\">",
"      Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35638?source=related_link\">",
"      Physiology of cholecystokinin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=related_link\">",
"      Physiology of gastrin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=related_link\">",
"      Physiology of somatostatin and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=related_link\">",
"      Synthesis, secretion, and regulation of gastrointestinal peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_33_16918="Cortisone acetate: Pediatric drug information";
var content_f16_33_16918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cortisone acetate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"    see \"Cortisone acetate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/18/19750?source=see_link\">",
"    see \"Cortisone acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"      see \"Cortisone acetate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depends upon the condition being treated and the response of the patient. Supplemental doses may be warranted during times of stress in the course of withdrawing therapy. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-inflammatory or immunosuppressive: 2.5-10 mg/kg/day or 20-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Physiologic replacement: 0.5-0.75 mg/kg/day or 20-25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 20-300 mg/day divided every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals, food, or milk to decrease GI effects",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of adrenocortical insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cortisone may be confused with Cardizem&reg;, Cortizone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hirsutism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Increased appetite, indigestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, glaucoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkalosis, Cushing's syndrome, delirium, edema, euphoria, fractures, hallucinations, hypersensitivity reactions, hypertension, hypokalemia, muscle wasting, myalgia, osteoporosis, pancreatitis, peptic ulcer, pituitary-adrenal axis suppression, pseudotumor cerebri, psychoses, seizure, skin atrophy, ulcerative esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cortisone, any component, or corticosteroids; serious infections, except septic shock or tuberculous meningitis; systemic fungal or viral infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-exisiting psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tesamorelin: May decrease serum concentrations of the active metabolite(s) of Cortisone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, phosphorus, and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Cortisone is found in cord blood; endogenous maternal cortisol (active) is metabolized by placental enzymes to cortisone (inactive), regulating the amount of maternal glucocorticoids reaching the fetus. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to cortisone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term use: Electrolytes, glucose, blood pressure, height, weight",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 30-36 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk; distributes to muscles, liver, skin, intestines, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile and urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/18/19750?source=see_link\">",
"      see \"Cortisone acetate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not discontinue or reduce dose without physician's approval; limit caffeine; avoid alcohol",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insoluble in water",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16918/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16918/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13182 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16918=[""].join("\n");
var outline_f16_33_16918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051942\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051934\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154710\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154697\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051946\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051945\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154767\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154765\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051950\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051933\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051932\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299096\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154706\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051952\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472607\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051941\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051931\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051948\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051949\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051939\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051951\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=related_link\">",
"      Cortisone acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/18/19750?source=related_link\">",
"      Cortisone acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_33_16919="Cefepime: Drug information";
var content_f16_33_16919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefepime: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/22/39267?source=see_link\">",
"    see \"Cefepime: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"    see \"Cefepime: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14482579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Seizure Risk with Cefepime",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA is reminding health care providers about the need to adjust the dosage of cefepime in patients with renal impairment. Cases of nonconvulsive status epilepticus have been associated with the use of cefepime, primarily in patients with renal impairment who did not receive appropriate dosage adjustments; however, some of the cases occurred in patients who appropriately received dosage adjustment according to their degree of renal impairment.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       To minimize the risk of seizures, healthcare providers should adjust the dosage of cefepime in patients with creatinine clearance &le;60 mL/minute. If seizure associated with cefepime therapy does occur, consider discontinuing cefepime or making appropriate adjustment in dosage, as necessary, based on renal function. The label is being revised to highlight this risk.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Maxipime&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Fourth Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brain abscess, postneurosurgical prevention (unlabeled use):",
"     </b>",
"     I.V.: 2 g every 8 hours with vancomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Febrile neutropenia, monotherapy:",
"     </b>",
"     I.V: 2 g every 8 hours for 7 days or until the neutropenia resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infections, complicated, severe (in combination with metronidazole):",
"     </b>",
"     I.V.: 2 g every 12 hours for 7-10 days.",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA  guidelines recommend 2 g every 8-12 hours for 4-7 days (provided source controlled). Not recommended for hospital-acquired intra-abdominal infections (IAI) associated with multidrug-resistant gram negative organisms or in mild-to-moderate community-acquired IAIs due to risk of toxicity and the development of resistant organisms (Solomkin, [IDSA] 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otitis externa, malignant (unlabeled use):",
"     </b>",
"     I.V.: 2 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia",
"     </b>",
"     : I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nosocomial (HAP/VAP)",
"     </i>",
"     : 1-2 g every 8-12 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Duration of therapy may vary considerably (7-21 days); usually longer courses are required if",
"     <i>",
"      Pseudomonas",
"     </i>",
"     . In absence of",
"     <i>",
"      Pseudomonas",
"     </i>",
"     , and if appropriate empiric treatment used and patient responsive, it may be clinically appropriate to reduce duration of therapy to 7-10 days (American Thoracic Society Guidelines, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Community-acquired (including pseudomonal):",
"     </i>",
"     1-2 g every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection,",
"     </b>",
"     <b>",
"      <i>",
"       Enterobacter spp",
"      </i>",
"     </b>",
"     <b>",
"      or",
"     </b>",
"     <b>",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     I.V.: 2 g every 12 hours for 4-6 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     When treating",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     , consider addition of an aminoglycoside (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Septic lateral/cavernous sinus thrombosis (unlabeled use):",
"     </b>",
"     I.V.: 2 g every 8-12 hours; with metronidazole for lateral",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure, uncomplicated:",
"     </b>",
"     I.V.: 2 g every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections, complicated and uncomplicated:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate",
"     </i>",
"     : I.M., I.V.: 0.5-1 g every 12 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe",
"     </i>",
"     : I.V.: 2 g every 12 hours for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"      see \"Cefepime: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Febrile neutropenia:",
"     </b>",
"     I.V.: 50 mg/kg/dose every 8 hours for 7 days or until neutropenia resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections (uncomplicated) and pneumonia:",
"     </b>",
"     I.V.: 50 mg/kg/dose every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections, complicated and uncomplicated:",
"     </b>",
"     I.V., I.M.: 50 mg/kg/dose every 12 hours for 7-10 days;",
"     <b>",
"      Note:",
"     </b>",
"     I.M. may be considered for mild-to-moderate infection only.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Children: No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, similar dosage adjustments to adults would be anticipated based on comparable pharmacokinetics between children and adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Adults: Recommended maintenance schedule based on creatinine clearance (may be estimated using the Cockcroft-Gault formula), compared to normal dosing schedule: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Cefepime Hydrochloride",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/minute)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Recommended Maintenance Schedule",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;60",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (normal recommended dosing schedule)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 8 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 12 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11-29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): I.V.: Initial: 1 g (single dose) on day 1. Maintenance: 0.5-1 g every 24 hours",
"     <b>",
"      or",
"     </b>",
"     1-2 g every 48-72 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of  3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Removed to a lesser extent than hemodialysis; administer normal recommended dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 2 g followed by 1-2 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     CVVHD/CVVHDF: Loading dose of 2 g followed by either 1 g every 8 hours",
"     <b>",
"      or",
"     </b>",
"     2 g every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage of 1 g every 8 hours results in similar steady-state concentrations as 2 g every 12 hours and is more cost effective (Heintz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider higher dosage of 4 g/day if treating",
"     <i>",
"      Pseudomonas",
"     </i>",
"     or life-threatening infections in order to maximize time above MIC (Trotman, 2005). Dosage of 2 g every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride: 1 g (50 mL); 2 g (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 500 mg, 1 g, 2 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F147298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered either I.M. or I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inject deep I.M. into large muscle mass. Inject direct I.V. over 5 minutes. Infuse intermittent infusion over 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, bacteriostatic water, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ampicillin/sulbactam, anidulafungin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cyclophosphamide, cytarabine, dactinomycin, dexamethasone sodium phosphate, dexmedetomidine, docetaxel, doxorubicin liposome, fenoldopam, fluconazole, fludarabine, fluorouracil, furosemide, gentamicin, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, insulin (regular), ketamine, leucovorin calcium, lorazepam, melphalan, mesna, methotrexate, methylprednisolone sodium succinate, metronidazole, milrinone, mycophenolate, paclitaxel, piperacillin/tazobactam, ranitidine, remifentanil, sargramostim, sodium bicarbonate, sufentanil, sulfamethoxazole/trimethoprim, telavancin, thiotepa, ticarcillin/clavulanate, tigecycline, tobramycin, valproate sodium, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acetylcysteine, acyclovir, amphotericin B, amphotericin B cholesteryl sulfate complex, caspofungin, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, dacarbazine, daunorubicin, diazepam, diphenhydramine, doxorubicin, droperidol, enalaprilat, erythromycin lactobionate, etoposide, etoposide phosphate, famotidine, filgrastim, floxuridine, gallium nitrate, ganciclovir, haloperidol, hydroxyzine, idarubicin, ifosfamide, magnesium sulfate, mannitol, mechlorethamine, meperidine, metoclopramide, midazolam, mitomycin, mitoxantrone, morphine, nalbuphine, nicardipine, ondansetron, phenytoin, prochlorperazine edisylate, promethazine, streptozocin, theophylline, vinblastine, vincristine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dobutamine, dopamine, morphine, propofol, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of uncomplicated and complicated urinary tract infections, including pyelonephritis caused by",
"     <i>",
"      Escherichia coli, Klebsiella pneumoniae",
"     </i>",
"     , or",
"     <i>",
"      Proteus mirabilis",
"     </i>",
"     ; monotherapy for febrile neutropenia; uncomplicated skin and skin structure infections caused by",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     or methicillin-susceptible staphylococci; moderate-to-severe pneumonia caused by",
"     <i>",
"      Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae",
"     </i>",
"     , or",
"     <i>",
"      Enterobacter",
"     </i>",
"     species; complicated intra-abdominal infections (in combination with metronidazole) caused by",
"     <i>",
"      E. coli, P. aeruginosa, K. pneumoniae, Enterobacter",
"     </i>",
"     species, or",
"     <i>",
"      Bacteroides fragilis",
"     </i>",
"     against methicillin-susceptible staphylococci,",
"     <i>",
"      Enterobacter",
"     </i>",
"     sp, and many other gram-negative bacilli.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children 2 months to 16 years: Empiric therapy of febrile neutropenia patients, uncomplicated skin/soft tissue infections, pneumonia, and uncomplicated/complicated urinary tract infections, including pyelonephritis.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9645320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brain abscess (postneurosurgical prevention); malignant otitis externa; prosthetic joint infection; septic lateral/cavernous sinus thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9645319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cefepime may be confused with cefixime, cefTAZidime",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hematologic: Positive Coombs' test without hemolysis (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1%), headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 4%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;3%), nausea (&le;2%), vomiting (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophils (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (3%), AST increased (2%), PTT abnormal (2%), PT abnormal (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Inflammation, phlebitis, and pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alkaline phosphatase increased, anaphylactic shock, anaphylaxis, bilirubin increased, BUN increased, colitis, coma, confusion, creatinine increased, encephalopathy, hallucinations, hematocrit decreased, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia, leucopenia, myoclonus, nonconvulsive status epilepticus, neutropenia, oral moniliasis, pseudomembranous colitis, seizure, stupor, thrombocytopenia, urticaria, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Aplastic anemia, erythema multiforme, hemolytic anemia, hemorrhage, pancytopenia, PT prolonged, renal dysfunction, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, toxic nephropathy, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefepime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Severe neurological reactions (some fatal) have been reported, including encephalopathy, myoclonus, seizures, and nonconvulsive status epilepticus.  Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function or discontinue therapy if patient develops neurotoxicity; effects are often reversible upon discontinuation of cefepime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, especially colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute); dosage adjustments recommended. May increase risk of encephalopathy, myoclonus, and seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5947925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cefepime crosses the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of cefepime are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefepime to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cefepime HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (50 mL): $31.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g/100 mL (100 mL): $51.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cefepime HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cefepime-Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (1): $13.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 gm/50 mL (1): $20.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F147304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Axepim (FR);",
"     </li>",
"     <li>",
"      Axera (PH);",
"     </li>",
"     <li>",
"      Caprifim (ID);",
"     </li>",
"     <li>",
"      Cefemax (TW);",
"     </li>",
"     <li>",
"      Cefepima (CO);",
"     </li>",
"     <li>",
"      Cefepitax (BR);",
"     </li>",
"     <li>",
"      Ceficad (IN);",
"     </li>",
"     <li>",
"      Cefinov (ID);",
"     </li>",
"     <li>",
"      Cepiram (PH);",
"     </li>",
"     <li>",
"      Dimipra (PH);",
"     </li>",
"     <li>",
"      Efectus (DO);",
"     </li>",
"     <li>",
"      Emax (ID);",
"     </li>",
"     <li>",
"      Exepime (ID);",
"     </li>",
"     <li>",
"      Forzyn Beta (PY);",
"     </li>",
"     <li>",
"      Funjapin (TW);",
"     </li>",
"     <li>",
"      Interprim (ID);",
"     </li>",
"     <li>",
"      Kabol (DO);",
"     </li>",
"     <li>",
"      Macef (ID);",
"     </li>",
"     <li>",
"      Macepim (TW);",
"     </li>",
"     <li>",
"      Maxcef (AR, UY);",
"     </li>",
"     <li>",
"      Maxef (MX);",
"     </li>",
"     <li>",
"      Maxfrom (AR);",
"     </li>",
"     <li>",
"      Maxicef (ID);",
"     </li>",
"     <li>",
"      Maxilan (ID);",
"     </li>",
"     <li>",
"      Maxipime (AT, AU, BE, BG, CH, CL, CN, CZ, DE, DK, EC, EE, ES, FI, GR, HK, HN, HU, IT, JP, KP, LU, MX, MY, NL, NZ, PE, PK, PL, PT, RU, SE, SG, TR, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Megapime (MY, TH);",
"     </li>",
"     <li>",
"      Pimcef (PE);",
"     </li>",
"     <li>",
"      Pime (TH);",
"     </li>",
"     <li>",
"      Procepim (ID);",
"     </li>",
"     <li>",
"      Rapime (ID);",
"     </li>",
"     <li>",
"      Rovatim (PH);",
"     </li>",
"     <li>",
"      Sanpime (PH);",
"     </li>",
"     <li>",
"      Sefpime (TH);",
"     </li>",
"     <li>",
"      Silex (PH);",
"     </li>",
"     <li>",
"      Supecef (TW);",
"     </li>",
"     <li>",
"      Zepim (PH);",
"     </li>",
"     <li>",
"      Zepime (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 16-20 L; penetrates into inflammatory fluid at concentrations ~80% of serum levels and into bronchial mucosa at levels ~60% of those reached in the plasma; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.M.: 1-2 hours; I.V.: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (85% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allaouchiche B, Breilh D, Jaumain H, et al, &ldquo;Pharmacokinetics of Cefepime During Continuous Veno-Venous Hemodiafiltration,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1997, 41(11):2424-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/9371344/pubmed\" id=\"9371344\" target=\"_blank\">",
"        9371344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas AG, Stutman HR, Zaleska M, et al, &ldquo;Cefepime. Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1992, 146(7):797-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/1496945/pubmed\" id=\"1496945\" target=\"_blank\">",
"        1496945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barbhaiya RH, Knupp CA, and Pittman KA, &ldquo;Effects of Age and Gender on Pharmacokinetics of Cefepime,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1992, 36(6):1181-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barradell LB and Bryson HM, &ldquo;Cefepime. A Review of Its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 47(3):471-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/7514976/pubmed\" id=\"7514976\" target=\"_blank\">",
"        7514976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Reed MD, Lemon E, et al, &ldquo;Pharmacokinetics (PK) of Cefepime in Pediatric Patients Administered Single and Multiple 50 mg/kg Doses Every 8 Hours by the Intravenous (I.V.) or Intramuscular (I.M.) Route,&rdquo; 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Orlando, Fl. Abs. A69.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garrelts JC, Wagner DJ, \"The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(12):1258-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/10630824/pubmed\" id=\"10630824\" target=\"_blank\">",
"        10630824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, \"Pharmacokinetics of Cefepime During Continuous Renal Replacement Therapy in Critically Ill Patients,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(11):3148-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/11600370/pubmed\" id=\"11600370\" target=\"_blank\">",
"        11600370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saez-Llorens X, Castano E, Garcia R, et al, &ldquo;Prospective Randomized Comparison of Cefepime and Cefotaxime for Treatment of Bacterial Meningitis in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1995, 39(4):937-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/7785999/pubmed\" id=\"7785999\" target=\"_blank\">",
"        7785999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yahav D, Paul M, Fraser A, et al, &ldquo;Efficacy and Safety of Cefepime: A Systematic Review and Meta-Analysis,&rdquo;",
"      <i>",
"       Lancet Infect Dis",
"      </i>",
"      , 2007, 7(5):338-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/33/16919/abstract-text/17448937/pubmed\" id=\"17448937\" target=\"_blank\">",
"        17448937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9215 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16919=[""].join("\n");
var outline_f16_33_16919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14482579\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147316\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147353\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147319\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147337\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147320\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147321\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682524\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147294\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147298\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147359\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147297\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645320\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645319\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147351\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147301\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147282\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298988\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147325\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147303\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323046\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147292\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147304\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147281\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147300\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9215|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/22/39267?source=related_link\">",
"      Cefepime: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=related_link\">",
"      Cefepime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_33_16920="Severe variable decelerations";
var content_f16_33_16920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Severe variable decelerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Variability is minimal to absent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce K Young, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16920=[""].join("\n");
var outline_f16_33_16920=null;
var title_f16_33_16921="Overview of malaria in pregnancy";
var content_f16_33_16921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of malaria in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Peter A Chedraui, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Blair J Wylie, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16921/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/33/16921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each year, 50 million women living in malaria-endemic areas become pregnant; one-half of these women live in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/1\">",
"     1",
"    </a>",
"    ]. It is estimated that 10,000 women and 200,000 infants die as a result of malaria infection during pregnancy; severe maternal anemia, prematurity, and low birth weight contribute to more than half of these deaths.",
"   </p>",
"   <p>",
"    Human malaria is caused by five species of Plasmodia: P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/2\">",
"     2",
"    </a>",
"    ]. Most infections are due to either P. falciparum or P. vivax, but mixed infections with more than one malarial species also occur. The majority of malaria-related deaths are due to P. falciparum.",
"   </p>",
"   <p>",
"    The continued public health burden of malaria is due to a combination of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing resistance of malarial parasites to chemotherapy",
"     </li>",
"     <li>",
"      Increasing resistance of the Anopheles mosquito vector to insecticides",
"     </li>",
"     <li>",
"      Ecologic and climate changes",
"     </li>",
"     <li>",
"      Increasing international travel to malaria-endemic areas by nonimmune travelers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some specific issues relating to malaria in pregnant women, primarily those who live in endemic areas, will be reviewed here. Universal issues regarding malaria, treatment of malaria in pregnancy, and travel of pregnant women to malarious areas are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=see_link\">",
"       \"Epidemiology, prevention, and control of malaria in endemic areas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"       \"Clinical manifestations of malaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"       \"Prevention of malaria infection in travelers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"       \"Treatment of uncomplicated falciparum malaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"       \"Treatment of severe falciparum malaria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE, MICROBIOLOGY, AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who reside in malaria endemic areas, the prevalence of malaria is higher in primigravidas than in nonpregnant women or multigravidas. P. falciparum is the predominant species giving rise to heightened morbidity and mortality in pregnancy.",
"   </p>",
"   <p>",
"    P. vivax infection can give rise to some of the same complications as P. falciparum; however, the complications are less frequent and less severe. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endemicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of malaria in pregnancy is related to intensity of transmission. Holo-endemic malaria refers to areas where there are very high rates of infection in the community (&gt;60 percent of children less than 5 years of age are infected) and the exposure to the parasite is stable. Therefore, women have more frequent lifetime malaria episodes, thus greater immunity, so tend to have milder complications.",
"   </p>",
"   <p>",
"    In contrast, mesoendemic malaria refers to areas where transmission is lower (&lt;20 percent of children less than 5 years of age are infected) and the exposure to the parasite is more unstable. With less exposure to the parasite, the development of natural immunity may be slower. Therefore pregnant women are more likely to develop severe complications such as pulmonary edema and hypoglycemia.",
"   </p>",
"   <p>",
"    Malaria in pregnancy has generally been studied in holo-endemic areas, such as Sub-Saharan Africa. In these areas, the median prevalence of maternal malaria (defined as peripheral or placental infection identified by microscopy) is 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mesoendemic areas, such as malaria endemic countries within the Americas, the prevalence of malaria is lower in both pregnant and nonpregnant women, although the rate appears to be rising. The median prevalence of malaria in pregnant women in low-transmission areas outside of Africa ranges from 1.8 to 17.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2010, 41 cases of malaria in pregnant women were reported to the CDC; eight cases were severe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/4\">",
"     4",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18921208\">",
"    <span class=\"h2\">",
"     Pregnant versus nonpregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of peripheral parasitemia is higher in pregnant than in age-matched nonpregnant women living in the same geographic area both in holo-endemic and mesoendemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. As an example, malaria surveillance in 430 pregnant and 250 nonpregnant women in Kinshasa found the prevalence of active malaria was 22 and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, in Gambia, the prevalence of parasitemia was 32 percent in pregnant women, but only 26 percent in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gravidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic areas, the prevalence of malaria (P. falciparum or P. vivax) generally decreases with increasing gravidity, but remains higher in pregnant women of any gravidity compared to nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/12\">",
"     12",
"    </a>",
"    ]. In Gambia, parasitemia was more common in primigravidas (64 percent) than in women having a",
"    <span class=\"nowrap\">",
"     second/third",
"    </span>",
"    pregnancy (29 percent) or who have had four or more pregnancies (21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/11\">",
"     11",
"    </a>",
"    ]. Others have reported a two-fold increase in infection prevalence among primigravidas compared to other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In contrast, low gravidity was not a risk factor for malarial infection in a study from Kinshasa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One possible explanation for this discordance is that in areas of low or episodic malaria endemicity (and therefore low immunity), all pregnant women are similarly susceptible to malaria infection, whereas in areas of high endemicity (and therefore high immunity), women are most susceptible during their first pregnancy, because they have not yet acquired sufficient pregnancy-specific immunity (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Placental malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the unique features of malaria in pregnancy is the ability of P. falciparum- parasitized erythrocytes to sequester within the intervillous space of the placenta (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathogenesis'",
"    </a>",
"    below). Notably, placental sequestration is not a feature of P. vivax infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median prevalence of placental malaria in areas of stable transmission is 26 percent, but may be even higher when more sensitive methods for diagnosis of placental infection, such as histology or polymerase chain reaction (PCR), are utilized rather than microscopy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to peripheral parasitemia, in holo-endemic regions the prevalence of placental malaria is higher in primigravidas (16 to 63 percent) than in multigravidas (12 to 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Overall, the average prevalence of placental malaria in primigravidas is 30 to 40 percent, twice the rate found in multigravidas.",
"   </p>",
"   <p>",
"    Placental infection may be detected even in the absence of peripheral parasitemia in mothers. In an area of stable malaria transmission in Tanzania, no parasites were observed in the maternal bloodstream of 46.3 percent of the women with histologic evidence of placental malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune responses occur following infection with malaria. Pregnancy selects for parasite clones that have the ability to adhere to the placenta. Partial immunity to these clones develops with successive pregnancies. Individuals living in endemic areas may develop partial immunity to disease following repeated infections and have a lower prevalence of parasitemia compared to nonimmunes. These individuals are referred to as \"semi-immune\" or having \"non-sterilizing immunity.\" Partial immunity does",
"    <strong>",
"     NOT",
"    </strong>",
"    prevent infection: following a bite by an infected mosquito, these individuals will still develop parasitemia, but the severity of symptoms is typically limited. Partial protection wanes quickly after leaving an endemic area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of malaria\", section on 'Immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy-associated P. falciparum malaria is characterized by sequestration and multiplication of a distinct population of malarial parasites in the placenta. These parasites express a specific class of variant surface antigens (VSAs) that mediate adhesion of parasite-infected erythrocytes to chondroitin sulfate A (CSA) on the syncytiotrophoblast lining the intervillous space [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This process appears to involve upregulated transcription of var2csa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/21\">",
"     21",
"    </a>",
"    ], which is expressed on the surface of CSA-adherent infected erythrocytes. This suggests that the var2csa gene encodes a parasite adhesion molecule that initiates the pathology associated with Pregnancy Associated Malaria (PAM).",
"   </p>",
"   <p>",
"    Once these parasites adhere to the surface of trophoblastic villi, they induce accumulation of inflammatory leukocytes. Histopathology of placentas with active malaria infection shows adhesion of infected erythrocytes to syncytiotrophoblast, syncytial degradation, increased syncytial knotting and, in rare cases, localized destruction of the villi [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/22\">",
"     22",
"    </a>",
"    ]. This process may be exacerbated by the development of neovasculature at an immunologically privileged site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/6,11,14,23\">",
"     6,11,14,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In holo-endemic areas, the frequency of both placental infection and poor pregnancy outcome decrease with successive pregnancies; nonimmune pregnant women, especially nulliparas, are at higher risk for adverse maternal-perinatal outcomes compared to multiparous controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/21,24-26\">",
"     21,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unique VSA types expressed on pregnancy-associated malaria (PAM) parasites can be serologically classified as sex specific (ie, men from malaria-endemic areas do not develop VSA antibodies) and gravidity dependent (ie, women acquire anti-VSA immunoglobulin G as a function of gravidity). Thus, the observed protection afforded multigravidas may result from maternal antibodies (eg, anti-VSA) that prevent cytoadhesion of the parasite to the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This theory is supported by the observation that primigravid women without histological evidence of PAM have uniformly low VSA-PAM-specific plasma IgG concentrations at delivery, which are not significantly different from those in unexposed pregnant women despite lifelong P. falciparum exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/28\">",
"     28",
"    </a>",
"    ]. Primigravid women with acute or chronic PAM have low-to-medium VSA-PAM IgG, likely indicating slow development of a primary response to VSA-PAM, while a high proportion of multigravid women have moderate-to-high VSA-PAM IgG values, suggesting fast and \"boostable\" memory responses that protect multigravidas from PAM and its complications (low birth weight, maternal anemia).",
"   </p>",
"   <p>",
"    Pregnancy-induced immune suppression may also account for the more severe disease experienced by primigravid nonimmune women. Primigravidas express higher cortisol levels compared with multiparous women, which leads to greater depression of cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/29\">",
"     29",
"    </a>",
"    ]. Other indirect support for the role of depressed cell-mediated immunity comes from the observation that specific malarial antibodies are not decreased during pregnancy, but when lymphocytes from pregnant women are challenged with malarial antigens, the lymphocyte proliferative responses are depressed compared to lymphocytes from nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation varies according to the underlying endemicity of the region. In areas of stable malaria transmission (holo-endemic regions) where partial immunity is common, most malarial infections in pregnant women are asymptomatic, but the mother remains at risk for anemia and the fetus is at risk for low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/23,32\">",
"     23,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Low birth weight'",
"    </a>",
"    below.) However, for women residing in mesoendemic areas, or for women returning to a holo-endemic area after a prolonged absence, malaria is more likely to result in febrile illness, severe symptomatic disease, preterm birth, and death of mother or fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ]. In areas of low or unstable malaria transmission where pregnant women have acquired little immunity, symptomatic malarial disease is the rule and serious complications may occur.",
"   </p>",
"   <p>",
"    Parasitemia peaks in the second trimester in both primigravidas and multigravidas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/6,11,13\">",
"     6,11,13",
"    </a>",
"    ], and the increased risk for pregnancy-associated malaria persists for 60 days postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/33\">",
"     33",
"    </a>",
"    ]. There is a semiquantitative relationship between the degree of parasitemia and severity of disease. P. falciparum is associated with especially high levels of parasitemia since it invades red cells of all ages; occasionally, more than 50 percent of red cells are infected.",
"   </p>",
"   <p>",
"    The clinical manifestations of malaria are nonspecific and variable. Virtually all nonimmune individuals will experience fever, which may or may not be periodic. Other frequent symptoms include: chills, sweats, headache, myalgias, fatigue, nausea, abdominal pain, vomiting, diarrhea, jaundice, and cough. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to nonpregnant women, pregnant women experience more severe disease, more hypoglycemia, and more respiratory complications (pulmonary edema, acute respiratory distress syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/34\">",
"     34",
"    </a>",
"    ]. Hypoglycemia occurs in 58 percent of gravid women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/35\">",
"     35",
"    </a>",
"    ] versus approximately 8 percent of nonpregnant adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/36\">",
"     36",
"    </a>",
"    ]. In holo-endemic regions, splenomegaly is noted in 10 to 23 percent of pregnant women and more often in pregnant women than nonpregnant controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia is a common complication of malaria in pregnancy; approximately 60 percent of pregnant women presenting with malarial infection are anemic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and anemia may be one of the few signs of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/40\">",
"     40",
"    </a>",
"    ]. However, anemia in resource poor countries can be due to one or more other etiologies, including nutritional deficiency, intestinal parasites (especially hookworm infections), and thalassemia trait. In one review, 5 to 10 percent of pregnant African women developed severe anemia (hemoglobin less than 7 to 8",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and one-quarter of these cases were attributed to malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ]. Some experts believe that malaria is a sufficiently common and serious cause of anemia in pregnant women in endemic areas that it is prudent to treat for malaria unless other causes of the anemia can be ascertained and respond to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=see_link\">",
"     \"Anemia in malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron deficiency may protect against placental malaria. A study of pregnant Tanzanian women found the prevalence of placental malaria was lower in iron deficient primigravidae than in primigravidae without iron deficiency (8.5 versus 47.3 percent, p&lt;0.0001) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/41\">",
"     41",
"    </a>",
"    ]. After the first pregnancy, the reduction in malaria prevalence with iron deficiency was maintained, but attenuated: secundigravidae (10.7 versus 31.6 percent, p&lt;0.01), multigravidae (5.1 versus 12.8 percent, P&lt;0.08). In addition, some studies in which iron supplements were given to primigravidae and children in areas where malaria and malnutrition are common have reported this intervention increased the rate of malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/42\">",
"     42",
"    </a>",
"    ]. Given that iron supplementation is routinely recommended during pregnancy, these findings highlight the need for large interventional trials evaluating the risks and benefits of iron supplementation in pregnant women who live in malarious areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postpartum infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk for both acquiring an infection and developing more severe disease persists for at least 60 to 70 days postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/33,43\">",
"     33,43",
"    </a>",
"    ]. Puerperal infection can also be caused by a new infection, rather than by parasites trapped in the placenta and released into the maternal blood at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/43\">",
"     43",
"    </a>",
"    ]. The reason for the high susceptibility to infection postpartum may be related to postpartum changes in the maternal immune system, maternal behavioral changes, or other undefined factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HIV COINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the standpoint of malarial disease, a seropositive HIV status increases the morbidity and mortality associated with the malaria infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]. Mothers with HIV may be at higher risk for malaria acquisition, placental malaria, higher parasite densities, and more severe clinical disease. After delivery, women with HIV and malaria are at increased risk for anemia compared to HIV seronegative women with or without malaria. Dual infection with malaria and HIV also leads to an increased risk of adverse perinatal outcomes. These issues and chemoprophylaxis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=see_link&amp;anchor=H14#H14\">",
"     \"HIV and malaria\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of malaria should be considered in any febrile woman who has resided in a malarious region, or traveled to a malarious region even if briefly or only in transit. Standard methods that detect peripheral parasitemia can be used in pregnant women, and include Giemsa-stained thick",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thin peripheral blood smears or rapid diagnostics. It is important to point out that women may have placental parasites that are not circulating in the peripheral blood, and hence, the blood film would be negative. No reliable peripheral biomarker for the presence of placental malaria has been identified; the diagnosis is made by histological examination after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse maternal and perinatal outcomes associated with malaria during pregnancy include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/5,9,11,38,51-56\">",
"     5,9,11,38,51-56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Miscarriage",
"     </li>",
"     <li>",
"      Fetal growth",
"      <span class=\"nowrap\">",
"       restriction/small",
"      </span>",
"      for gestational age (SGA) infant",
"     </li>",
"     <li>",
"      Preterm birth (&lt;37 weeks of gestation)",
"     </li>",
"     <li>",
"      Low birth weight (LBW) (&lt;2500 g at birth)",
"     </li>",
"     <li>",
"      Perinatal death",
"     </li>",
"     <li>",
"      Congenital infection",
"     </li>",
"     <li>",
"      Maternal anemia",
"     </li>",
"     <li>",
"      Maternal death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed above, in regions of unstable endemism, or when malaria is acquired in a nonimmune individual, malaria is more likely to result in severe maternal disease, preterm birth, and death of mother or fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ]. In areas where malaria is endemic, women have usually acquired sufficient immunity to prevent febrile illness, and they are less likely to experience preterm birth and the severe maternal complications of malaria. Nonetheless, asymptomatic mothers remain at risk for anemia, and their fetuses remain at risk for impaired growth (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Low birth weight'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    In a review of 117 studies published between 1985 and 2000 from endemic areas in sub-Saharan Africa, the population attributable risks for adverse birth outcomes associated with malaria were marked: anemia (3 to 15 percent), LBW (8 to 14 percent), growth restriction (13 to 70 percent), and infant mortality (3 to 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/57\">",
"     57",
"    </a>",
"    ]. In another review, it was estimated that in endemic areas approximately 19 percent of LBW infants result from maternal malaria infection, and 6 percent of infant deaths have been attributed to malaria-related LBW. These estimates imply that 100,000 infant deaths each year could be due to LBW caused by malaria during pregnancy in areas of malaria endemicity in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors related to increased severity of malarial infection during gestation and, therefore, an increased risk of adverse maternal and perinatal outcome include: low parity, young maternal age, nonimmune immunological status, P. falciparum or P. vivax protozoan species, a high degree of parasitemia and placental infection, as well as the patient's socioeconomic background, place of residency (rural or urban), and season of acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/38,59-63\">",
"     38,59-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18921328\">",
"    <span class=\"h2\">",
"     P. vivax",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of P. vivax infection have been considered less striking than those of P. falciparum infection. This is likely related to the lack of placental",
"    <span class=\"nowrap\">",
"     sequestration/inflammation",
"    </span>",
"    with P. vivax and its moderate impact in causing anemia given that it only infects reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/16,64\">",
"     16,64",
"    </a>",
"    ]. Nonetheless, P. vivax is also associated with a significant risk of adverse maternal and fetal outcomes (eg, death, anemia, low birthweight) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/12,65,66\">",
"     12,65,66",
"    </a>",
"    ]. Like P. falciparum, P. vivax infection is more common in primigravid than multigravid women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32534014\">",
"    <span class=\"h2\">",
"     Miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of pregnancy outcome in over 17,000 pregnant women attending antenatal clinics at the Thai-Burmese border included 945 women with first trimester malaria, of whom 773 were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/56\">",
"     56",
"    </a>",
"    ]. After adjustment for maternal age, previous miscarriages, smoking, and non-malaria febrile illness, the odds of miscarriage in women with P. falciparum or P. vivax malaria were about three-fold higher than in women without malaria. The frequency of miscarriage in women without malaria, those with treated malaria, and all women with malaria (treated and untreated) was 19, 27, and 35 percent, respectively. The risk of miscarriage was increased for both symptomatic and asymptomatic malaria, but highest with symptomatic disease. The risk was similar for both P falciparum and P vivax infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased prevalence of preterm deliveries among women who become infected with P. falciparum during pregnancy may be mediated by alterations in cytokine production. In particular, infected women have an increased concentration of tumor necrosis factor-alpha (TNF-alpha) in the intervillous circulation, and the concentration of TNF-alpha correlates with the density of P. falciparum-infected erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Production of TNF-alpha plays a role in the pathogenesis of preterm birth and LBW. Individuals who carry the TNF 2 polymorphism in the promoter region of the TNF-alpha gene have heightened TNF-alpha production in response to infection, which increases their risk of preterm delivery, severe infection, and cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Low birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancies complicated by malaria, both fetal growth restriction and preterm birth contribute to LBW. Distinguishing between the two is challenging in resource-poor settings where ultrasound dating of pregnancy is usually not available and maternal recall of the last menstrual period is poor. In some settings, malaria has been estimated to be responsible for up to 70 percent of fetal growth restriction and up to 25 percent of LBW [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar birth weight reductions and attributable fractions of malaria-associated LBW have been reported from areas of stable and unstable malaria transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired fetal growth is correlated most strongly with evidence of parasites in the placenta and the corresponding inflammatory infiltrate. It has been hypothesized that malarial infection of the placenta leads to placental thickening and fibrin deposition, thereby decreasing placental transport of oxygen and nutrients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/11\">",
"     11",
"    </a>",
"    ]. Doppler studies have demonstrated impaired uteroplacental blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean birth weight of infants born to mothers with no evidence of malarial placental infection is higher than for those newborns from infected placentas (2763 versus 2143 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/72\">",
"     72",
"    </a>",
"    ]. A significant decrease (150 g) in the average birth weight of infants of primigravidas with placental malaria has been reported, but this decrease was not significant (52 g) in offspring of multigravidas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/11\">",
"     11",
"    </a>",
"    ]. This is related to the observation that primigravidas are more likely to have placental malaria and heavier parasite loads and are less likely to have partial immunity. Support for this theory was illustrated in a study that showed affected multigravidas had higher plasma levels of anti-VAR2CSA IgG, gave birth to markedly heavier babies, and had a significantly lower risk of delivering LBW children than affected primigravid women in whom anti-VAR2CSA IgG levels were low and placental sequestration was increased [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/21\">",
"     21",
"    </a>",
"    ]. The level of adhesion of placental parasites to chondroitin sulfate receptors also appears to be an important risk factor for LBW [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assumption of causality is confounded by the frequent concomitant presence of anemia in primigravidas with placental malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/6,11,32\">",
"     6,11,32",
"    </a>",
"    ], which is independently associated with low birth weight. Indeed, when controlling for this confounding variable, the relationship between malaria and LBW becomes insignificant. However, since malaria is often the cause of the anemia, an association remains clinically compelling. A cohort study from Malawi including 2462 pregnant women found that an increasing number of P. falciparum infections during pregnancy increased the risks of both LBW and maternal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, second trimester infection increased the risk of LBW more than third trimester infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Perinatal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 117 studies published between 1948 and 2002 found that perinatal mortality (PNM) and fetal mortality were higher in malaria endemic countries than in nonendemic ones (PNM",
"    <span class=\"nowrap\">",
"     61.1/1000",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     25.8/1000",
"    </span>",
"    and fetal mortality",
"    <span class=\"nowrap\">",
"     40.1/1000",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     20.0/1000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/75\">",
"     75",
"    </a>",
"    ]. In a subset of nine of these studies that evaluated the correlation of fetal demise with placental malaria, presence of the latter significantly increased the risk for stillbirth, regardless of the number of prior pregnancies (OR 2.19, 95% CI 1.49-3.22) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;All types of malaria can be transmitted congenitally, but congenital disease is most often associated with P. vivax and P. falciparum. Placental infection is a prerequisite for, but does not predict, congenital disease. Placental infection is more common than cord blood parasitemia, which is more common than parasites on the infant's peripheral smear. In a Central African study of women who did not receive antimalarial agents during pregnancy, the rates of placental infection, cord blood parasitemia, and infant's peripheral smear parasitemia were 74, 6, and 3.6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In immune mothers, the risk of transplacental transmission of malaria appears to be small (0.1 to 1.5 percent of infants had cord blood positive for parasites and clinical disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/8,77\">",
"     8,77",
"    </a>",
"    ]. The rate is somewhat higher in women with overt attacks during pregnancy (1 to 4 percent risk of congenital infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/78\">",
"     78",
"    </a>",
"    ]. The low incidence of fetal infection despite the known high incidence of placental infection is presumably secondary to passive immunization by transplacental acquisition of maternal antibody. Transplacental passage of malarial antigens capable of priming the neonatal immune system has also been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in semi-immune or nonimmune mothers, transplacental antibody transfer may be deficient, and the incidence of congenital infection appears to be higher (7 to 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/55,80,81\">",
"     55,80,81",
"    </a>",
"    ]. In addition, maternal antibody levels are lower and the risk of congenital infection is higher in women who move from endemic areas to malaria-free locales where they are no longer frequently exposed to the disease.",
"   </p>",
"   <p>",
"    In endemic areas, it can be difficult to distinguish malaria acquired congenitally from that acquired as a newborn, particularly in infants of asymptomatic mothers. The onset of symptoms is usually at 2 to 8 weeks of age and includes poor feeding, fever, vomiting, diarrhea, and irritability. Anemia, thrombocytopenia, and hyperbilirubinemia are common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/55\">",
"     55",
"    </a>",
"    ]. Splenomegaly is more common than hepatomegaly.",
"   </p>",
"   <p>",
"    There have been five cases of congenital malaria reported in the United States since 2000. In one case report, the infected seven-month old infant presented with fever and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/82\">",
"     82",
"    </a>",
"    ]. Peripheral smears revealed malarial parasites with morphology consistent with P. vivax. Investigation by the public health department found that the mother had emigrated from Guatemala two years earlier and had a history of malaria with relapse while residing in her native country. The prenatal evaluation did not include any questions regarding a prior history of malaria, which may have contributed to the delay in diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maternal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) estimated that 10,000 maternal deaths each year are associated with malaria infection during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/1\">",
"     1",
"    </a>",
"    ]. Malaria is a leading cause of maternal mortality in regions of unstable endemism where there are periodic epidemics among nonimmune patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/83\">",
"     83",
"    </a>",
"    ]. A review of all pregnancy-related maternal deaths in an urban Mozambique setting between 1989 and 1993 identified 239 maternal deaths (320 maternal",
"    <span class=\"nowrap\">",
"     deaths/100,000",
"    </span>",
"    live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/51\">",
"     51",
"    </a>",
"    ]. In this series, 15.5 percent of the deaths were directly attributable to malaria, and 19.7 percent of the women who died were parasitemic with P. falciparum. Over one-third of the malaria-related deaths occurred in primigravid adolescents, primarily associated with severe anemia. Autopsies on 161 women showed that 44 (27.3 percent) had histological evidence of splenic malarial infection.",
"   </p>",
"   <p>",
"    A study performed at the main referral hospital in Gambia estimated that, during the malaria season, there was a 168 percent increase in the maternal mortality rate and a three-fold increase in the proportion of deaths due to anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/84\">",
"     84",
"    </a>",
"    ]. It was estimated that malaria accounted for up to 93 maternal deaths per 100,000 live births.",
"   </p>",
"   <p>",
"    Younger maternal age has been associated with higher rates of anemia and poorer maternal and fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. Adolescents have a significantly higher rate of anemia and SGA neonates than adults (anemia: 83 and 53 percent, respectively; SGA: 50 versus 27 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/38\">",
"     38",
"    </a>",
"    ]. Adolescents in rural areas at earlier gestations are at higher risk of malarial infection and this infection is strongly associated with anemia (particularly during the dry season) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/85\">",
"     85",
"    </a>",
"    ]. This suggests that control measures against malaria infection be targeted at younger rural women early in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16921/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF MALARIA AND MANAGEMENT OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;These topics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=see_link\">",
"       \"Patient information: Malaria (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to nonpregnant women,",
"      <span class=\"nowrap\">",
"       pregnant/postpartum",
"      </span>",
"      women are at increased risk of both acquiring malaria and developing more severe disease. One of the unique features of malaria in pregnancy is the ability of P. falciparum- parasitized erythrocytes to sequester within the intervillous space of the placenta. Placental infection and poor pregnancy outcome decrease in frequency with successive pregnancies for women who reside in endemic areas: nonimmune pregnant women, especially nulliparas, are at higher risk of adverse maternal-perinatal outcome than multiparous women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence, microbiology, and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy-associated malaria is characterized by sequestration and multiplication of a distinct population of malarial parasites in the placenta. These parasites express a specific class of variant surface antigens (VSAs) that mediate adhesion of parasite-infected erythrocytes to chondroitin sulfate A (CSA) on the syncytiotrophoblast lining the intervillous space. Once these parasites adhere to the surface of trophoblastic villi, they induce accumulation of inflammatory leukocytes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation varies according to the underlying endemicity of the region. Parasitemia peaks in the second trimester in both primigravidas and multigravidas, and the increased risk for pregnancy-associated malaria persists for 60 days postpartum. Anemia and hypoglycemia are common maternal clinical manifestations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of malaria should be considered in any febrile pregnant woman who has traveled to or resided in a malarious region, even if briefly or only in transit. Peripheral blood smears are typically used for diagnosis, but may be negative in women with placental malaria who are otherwise asymptomatic. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse perinatal outcomes associated with malaria include miscarriage, fetal growth",
"      <span class=\"nowrap\">",
"       restriction/small",
"      </span>",
"      for gestational age infant, preterm birth, low birth weight, perinatal death, and congenital infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://mosquito.who.int/. (Accessed May 8, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/2\">",
"      Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/3\">",
"      Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     Mali S, Kachur AP, Arguin, PM. Malaria surveillance - United States, 2010. MMWR March 2, 2012. www.cdc.gov/mmwr/preview/mmwrhtml/ss6102a1.htm?s_cid=ss6102a1_e (Accessed on March 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/5\">",
"      Singh N, Saxena A, Chand SK, et al. Studies on malaria during pregnancy in a tribal area of central India (Madhya Pradesh). Southeast Asian J Trop Med Public Health 1998; 29:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/6\">",
"      Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ 1983; 61:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/7\">",
"      Diagne N, Rogier C, Cisse B, Trape JF. Incidence of clinical malaria in pregnant women exposed to intense perennial transmission. Trans R Soc Trop Med Hyg 1997; 91:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/8\">",
"      Bergstr&ouml;m S, Fernandes A, Schwalbach J, et al. Materno-fetal transmission of pregnancy malaria: an immunoparasitological study on 202 parturients in Maputo. Gynecol Obstet Invest 1993; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/9\">",
"      Sholapurkar SL, Gupta AN, Mahajan RC. Clinical course of malaria in pregnancy--a prospective controlled study from India. Trans R Soc Trop Med Hyg 1988; 82:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/10\">",
"      Mbanzulu PN, Leng JJ, Kaba S, et al. [Malaria and pregnancy. Epidemiological situation in Kinshasa (Za&iuml;re)]. Rev Fr Gynecol Obstet 1988; 83:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/11\">",
"      McGregor IA. Epidemiology, malaria and pregnancy. Am J Trop Med Hyg 1984; 33:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/12\">",
"      Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999; 354:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/13\">",
"      Nosten F, ter Kuile F, Maelankirri L, et al. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 1991; 85:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/14\">",
"      Mutabingwa TK. Malaria and pregnancy: epidemiology, pathophysiology and control options. Acta Trop 1994; 57:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/15\">",
"      Bouyou-Akotet MK, Ionete-Collard DE, Mabika-Manfoumbi M, et al. Prevalence of Plasmodium falciparum infection in pregnant women in Gabon. Malar J 2003; 2:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/16\">",
"      McGready R, Davison BB, Stepniewska K, et al. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg 2004; 70:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/17\">",
"      Rogerson SJ, Mkundika P, Kanjala MK. Diagnosis of Plasmodium falciparum malaria at delivery: comparison of blood film preparation methods and of blood films with histology. J Clin Microbiol 2003; 41:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/18\">",
"      Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 2000; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/19\">",
"      Salanti A, Staalsoe T, Lavstsen T, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003; 49:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/20\">",
"      Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996; 272:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/21\">",
"      Salanti A, Dahlb&auml;ck M, Turner L, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004; 200:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/22\">",
"      Crocker IP, Tanner OM, Myers JE, et al. Syncytiotrophoblast degradation and the pathophysiology of the malaria-infected placenta. Placenta 2004; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/23\">",
"      McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg 1983; 77:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/24\">",
"      Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 2003; 97:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/25\">",
"      Fried M, Duffy PE. Maternal malaria and parasite adhesion. J Mol Med (Berl) 1998; 76:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/26\">",
"      Andrews KT, Lanzer M. Maternal malaria: Plasmodium falciparum sequestration in the placenta. Parasitol Res 2002; 88:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/27\">",
"      Beeson JG, Rogerson SJ, Elliott SR, Duffy MF. Targets of protective antibodies to malaria during pregnancy. J Infect Dis 2005; 192:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/28\">",
"      Staalsoe T, Shulman CE, Bulmer JN, et al. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/29\">",
"      Vleugels MP, Eling WM, Rolland R, de Graaf R. Cortisol and loss of malaria immunity in human pregnancy. Br J Obstet Gynaecol 1987; 94:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/30\">",
"      Rasheed FN, Bulmer JN, Dunn DT, et al. Suppressed peripheral and placental blood lymphoproliferative responses in first pregnancies: relevance to malaria. Am J Trop Med Hyg 1993; 48:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/31\">",
"      Riley EM, Schneider G, Sambou I, Greenwood BM. Suppression of cell-mediated immune responses to malaria antigens in pregnant Gambian women. Am J Trop Med Hyg 1989; 40:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/32\">",
"      Brabin BJ, Ginny M, Sapau J, et al. Consequences of maternal anaemia on outcome of pregnancy in a malaria endemic area in Papua New Guinea. Ann Trop Med Parasitol 1990; 84:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/33\">",
"      Diagne N, Rogier C, Sokhna CS, et al. Increased susceptibility to malaria during the early postpartum period. N Engl J Med 2000; 343:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/34\">",
"      Warrell, DA, Molyneuz, ME, Beales, PF. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/35\">",
"      Saeed BO, Atabani GS, Nawwaf A, et al. Hypoglycaemia in pregnant women with malaria. Trans R Soc Trop Med Hyg 1990; 84:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/36\">",
"      White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/37\">",
"      Egwunyenga OA, Ajayi JA, Duhlinska-Popova DD. Malaria in pregnancy in Nigerians: seasonality and relationship to splenomegaly and anaemia. Indian J Malariol 1997; 34:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/38\">",
"      Espinoza E, Hidalgo L, Chedraui P. The effect of malarial infection on maternal-fetal outcome in Ecuador. J Matern Fetal Neonatal Med 2005; 18:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/39\">",
"      Assabri AM, Muharram AA. Malaria in pregnancy in Hodiedah, Republic of Yemen. East Mediterr Health J 2002; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/40\">",
"      Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG 2005; 112:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/41\">",
"      Kabyemela ER, Fried M, Kurtis JD, et al. Decreased susceptibility to Plasmodium falciparum infection in pregnant women with iron deficiency. J Infect Dis 2008; 198:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/42\">",
"      Oppenheimer SJ, Gibson FD, Macfarlane SB, et al. Iron supplementation increases prevalence and effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg 1986; 80:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/43\">",
"      Ramharter M, Grobusch MP, Kiessling G, et al. Clinical and parasitological characteristics of puerperal malaria. J Infect Dis 2005; 191:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/44\">",
"      Ticconi C, Mapfumo M, Dorrucci M, et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr 2003; 34:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/45\">",
"      ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/46\">",
"      Ayisi JG, van Eijk AM, ter Kuile FO, et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 2003; 17:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/47\">",
"      Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996; 55:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/48\">",
"      Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004; 363:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/49\">",
"      Bloland PB, Wirima JJ, Steketee RW, et al. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995; 9:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/50\">",
"      Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/51\">",
"      Granja AC, Machungo F, Gomes A, et al. Malaria-related maternal mortality in urban Mozambique. Ann Trop Med Parasitol 1998; 92:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/52\">",
"      Carles G, Bousquet F, Raynal P, et al. [Pregnancy and malaria. Study of 143 cases in French Guyana]. J Gynecol Obstet Biol Reprod (Paris) 1998; 27:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/53\">",
"      McGregor IA. Thoughts on malaria in pregnancy with consideration of some factors which influence remedial strategies. Parassitologia 1987; 29:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/54\">",
"      Newman RD, Hailemariam A, Jimma D, et al. Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic year. J Infect Dis 2003; 187:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/55\">",
"      Hulbert TV. Congenital malaria in the United States: report of a case and review. Clin Infect Dis 1992; 14:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/56\">",
"      McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012; 12:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/57\">",
"      Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/58\">",
"      Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev 2004; 17:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/59\">",
"      Akingbade OA. Embryotoxic and growth-retarding effects of malaria on pregnant mice. J Reprod Med 1992; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/60\">",
"      Duffy PE, Fried M. Plasmodium falciparum adhesion in the placenta. Curr Opin Microbiol 2003; 6:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/61\">",
"      Nathwani D, Currie PF, Douglas JG, et al. Plasmodium falciparum malaria in pregnancy: a review. Br J Obstet Gynaecol 1992; 99:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/62\">",
"      Okoko BJ, Ota MO, Yamuah LK, et al. Influence of placental malaria infection on foetal outcome in the Gambia: twenty years after Ian Mcgregor. J Health Popul Nutr 2002; 20:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/63\">",
"      Redd SC, Wirima JJ, Steketee RW, et al. Transplacental transmission of Plasmodium falciparum in rural Malawi. Am J Trop Med Hyg 1996; 55:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/64\">",
"      Mayor A, Bardaj&iacute; A, Felger I, et al. Placental infection with Plasmodium vivax: a histopathological and molecular study. J Infect Dis 2012; 206:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/65\">",
"      Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008; 46:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/66\">",
"      Singh N, Shukla MM, Sharma VP. Epidemiology of malaria in pregnancy in central India. Bull World Health Organ 1999; 77:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/67\">",
"      Suguitan AL Jr, Cadigan TJ, Nguyen TA, et al. Malaria-associated cytokine changes in the placenta of women with pre-term deliveries in Yaounde, Cameroon. Am J Trop Med Hyg 2003; 69:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/68\">",
"      Suguitan AL Jr, Leke RG, Fouda G, et al. Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis 2003; 188:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/69\">",
"      Fried M, Muga RO, Misore AO, Duffy PE. Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. J Immunol 1998; 160:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/70\">",
"      Aidoo M, McElroy PD, Kolczak MS, et al. Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet Epidemiol 2001; 21:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/71\">",
"      Dorman EK, Shulman CE, Kingdom J, et al. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria. Ultrasound Obstet Gynecol 2002; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/72\">",
"      Kaushik A, Sharma VK, Kumar R, et al. Malarial placental infection and low birth weight babies. Mater Med Pol 1992; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/73\">",
"      Tuikue Ndam NG, Fievet N, Bertin G, et al. Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. J Infect Dis 2004; 190:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/74\">",
"      Kalilani L, Mofolo I, Chaponda M, et al. The effect of timing and frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and maternal anemia. Trans R Soc Trop Med Hyg 2010; 104:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/75\">",
"      van Geertruyden JP, Thomas F, Erhart A, D'Alessandro U. The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 2004; 71:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/76\">",
"      Schwetz, J, Peel, M. Congenital malaria and placental infections among Negroes of Central Africa. Trans R Soc Trop Med Hyg 1934; 28:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/77\">",
"      Subramanian D, Moise KJ Jr, White AC Jr. Imported malaria in pregnancy: report of four cases and review of management. Clin Infect Dis 1992; 15:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/78\">",
"      COVELL G. Congenital malaria. Trop Dis Bull 1950; 47:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/79\">",
"      Metenou S, Suguitan AL Jr, Long C, et al. Fetal immune responses to Plasmodium falciparum antigens in a malaria-endemic region of Cameroon. J Immunol 2007; 178:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/80\">",
"      Darie H, Haba M. [Congenital malaria]. Med Trop (Mars) 1992; 52:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/81\">",
"      Lee WW, Singh M, Tan CL. A recent case of congenital malaria in Singapore. Singapore Med J 1996; 37:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/82\">",
"      Congenital malaria - Nassau County, New York, 2004. Morb Mortal Wkly Rep 2005; 54:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/83\">",
"      Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet 1985; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/84\">",
"      Anya SE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factor. Am J Trop Med Hyg 2004; 70:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16921/abstract/85\">",
"      Dicko A, Mantel C, Thera MA, et al. Risk factors for malaria infection and anemia for pregnant women in the Sahel area of Bandiagara, Mali. Acta Trop 2003; 89:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4795 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16921=[""].join("\n");
var outline_f16_33_16921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE, MICROBIOLOGY, AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endemicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18921208\">",
"      Pregnant versus nonpregnant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gravidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Placental malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postpartum infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV COINFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18921328\">",
"      P. vivax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32534014\">",
"      Miscarriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Low birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Perinatal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF MALARIA AND MANAGEMENT OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=related_link\">",
"      Anemia in malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=related_link\">",
"      Epidemiology, prevention, and control of malaria in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=related_link\">",
"      Pathogenesis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=related_link\">",
"      Patient information: Malaria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_33_16922="Management of asymptomatic carotid atherosclerotic disease";
var content_f16_33_16922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of asymptomatic carotid atherosclerotic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Ronald M Fairman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/33/16922/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/33/16922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The locations most frequently affected by carotid atherosclerosis are the proximal internal carotid artery (ie, the origin) and the carotid bifurcation. Progression of atheromatous plaque at the carotid bifurcation results in luminal narrowing, often accompanied by ulceration. This process can lead to ischemic stroke or transient ischemic attack (TIA) from embolization, thrombosis, or hemodynamic compromise.",
"   </p>",
"   <p>",
"    Carotid endarterectomy (CEA) is established as safe and effective by randomized controlled trials for reducing the risk of ischemic stroke in both symptomatic and asymptomatic patients with carotid artery atherosclerosis. Advances in medical management and percutaneous carotid angioplasty and stenting (CAS) are proposed alternatives to CEA that may impact the future use of surgical revascularization techniques for carotid disease.",
"   </p>",
"   <p>",
"    This topic will review the treatment of asymptomatic carotid atherosclerotic disease. The management of symptomatic carotid disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of carotid occlusive disease are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link\">",
"     \"Carotid endarterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAROTID ENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials have established that carotid endarterectomy (CEA) is beneficial for selected patients with asymptomatic internal carotid artery stenosis of 60 to 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, the degree of benefit is not as great as it is for symptomatic carotid stenosis. In addition, the evidence supporting CEA for asymptomatic carotid disease is less compelling for women than for men. Therefore, careful patient selection is particularly important and should be guided by individual factors.",
"   </p>",
"   <p>",
"    Given the available data discussed below, we suggest CEA for medically stable men with asymptomatic carotid stenosis of 60 to 99 percent who have a life expectancy of at least five years, provided the perioperative risk of stroke and death for the surgeon or center is &lt;3 percent. We suggest medical management rather than CEA for women with asymptomatic carotid stenosis. Our recommendations are based upon data from randomized controlled trials, treatment guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/4-6\">",
"     4-6",
"    </a>",
"    ] and clinical experience. However, the management of asymptomatic carotid stenosis remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], and many experts favor CEA for select patients, regardless of gender, with high-grade asymptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is recommended for all patients who are having CEA. Aspirin should be started prior to surgery and continued for at least three months after surgery. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838520#H93838520\">",
"     \"Carotid endarterectomy\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endarterectomy trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of CEA for patients with asymptomatic high-grade carotid stenosis has been evaluated in three high-quality randomized controlled trials. These were the Veterans Affairs Cooperative Study Group (VA trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/1\">",
"     1",
"    </a>",
"    ], the Asymptomatic Carotid Atherosclerosis Study (ACAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/2\">",
"     2",
"    </a>",
"    ], and the Asymptomatic Carotid Surgery Trial (ACST) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of these trials found that CEA for asymptomatic carotid stenosis is associated with a small absolute risk reduction (ARR) for the outcome of any stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the VA trial, the ARR was 1.0 percent over a mean follow-up of 4 years",
"     </li>",
"     <li>",
"      In ACAS, the ARR was 3.0 percent over 2.7 years",
"     </li>",
"     <li>",
"      In ACST, the ARR was 3.1 percent over 3.4 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the ARR in the two largest trials (ACAS and ACST) was about 3 percent over three years for the outcome of any stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/10\">",
"     10",
"    </a>",
"    ]; the corresponding number needed to treat (NNT) to prevent one stroke at three years was approximately 33.",
"   </p>",
"   <p>",
"    Findings of the individual trials are discussed in the following sections. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'VA trial'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'ACAS trial'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'ACST trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     VA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multicenter VA trial randomly assigned 444 men with 50 to 99 percent asymptomatic carotid stenosis, as assessed by arteriogram, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone or aspirin plus CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/1\">",
"     1",
"    </a>",
"    ]. The end point was the combined incidence of TIA, transient monocular blindness, and stroke. After an average follow-up of almost 48 months, the CEA plus aspirin group compared with aspirin alone showed the following outcomes (",
"    <a class=\"graphic graphic_figure graphicRef53736 \" href=\"UTD.htm?23/50/24366\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower incidence in the primary endpoint of stroke or TIA (8 versus 20.6 percent) for a relative risk reduction of 0.38 (95% CI 0.22-0.67)",
"     </li>",
"     <li>",
"      A nonsignificantly lower incidence of ipsilateral stroke (4.7 versus 9.4 percent)",
"     </li>",
"     <li>",
"      No difference in the combined stroke and death rate at 30 days or 48 months (41 versus 44 percent); most of the deaths were due to coronary artery disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study has been criticized for including TIA in the primary end point, since by definition TIA does not result in any persistent neurologic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     ACAS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACAS trial randomized 1662 adults (ages 40 to 79 years) with 60 to 99 percent carotid stenosis, assessed with ultrasound and arteriogram, to CEA and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or aspirin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/2\">",
"     2",
"    </a>",
"    ]. The primary end point was cerebral infarction occurring in the distribution of the study artery or any stroke or death occurring in the perioperative period.",
"   </p>",
"   <p>",
"    After a median follow-up of 2.7 years, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of ipsilateral stroke and any perioperative stroke or death rate was significantly lower in the surgical group than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone (5 versus 11 percent) for a relative risk reduction of 0.53 (95% CI 0.22-0.72).",
"     </li>",
"     <li>",
"      The incidence of major ipsilateral stroke, major perioperative stroke, and perioperative death was nonsignificantly lower in the surgical group compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone (3.4 versus 6 percent) (",
"      <a class=\"graphic graphic_figure graphicRef54275 \" href=\"UTD.htm?21/30/21998\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The study was not powered to determine gender differences. However, subgroup analysis suggested that CEA was less effective in women. Men had an absolute risk reduction of 8 percent; the absolute risk reduction in women was only 1.4 percent, perhaps due to a higher incidence of perioperative complications in women compared with men (3.6 versus 1.7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     ACST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACST is the largest multicenter study of asymptomatic carotid surgery that found benefit for CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. From 1993 to 2003, the ACST randomly assigned 3120 patients (ages 40 to 91 years) with &ge;60 percent asymptomatic carotid stenosis by duplex ultrasound to immediate CEA or deferral of CEA until a definite indication occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ]. In the immediate CEA group, one-half were treated with CEA by one month, and 88 percent by one year. In the deferral group, about 4 percent of patients per year received CEA.",
"   </p>",
"   <p>",
"    All other aspects of management in both treatment groups were left to the discretion of treating physicians. Exclusion criteria included previous ipsilateral CEA, poor surgical risk, and probable cardiac source of emboli. The main end points were perioperative mortality and morbidity (stroke and myocardial infarction) and nonperioperative stroke. The main analysis for ACST combined ipsilateral and contralateral strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a mean of 3.4 years of follow-up and with adjustment for perioperative events, the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CEA group had a perioperative risk of stroke or death of 3.1 percent within 30 days of surgery.",
"     </li>",
"     <li>",
"      The net five-year risk for all strokes or perioperative death in the immediate CEA group was reduced by nearly half compared with the CEA deferral group (6.4 versus 11.8 percent, 95% CI 2.96-7.75) (",
"      <a class=\"graphic graphic_figure graphicRef51041 \" href=\"UTD.htm?33/23/34173\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similar benefit was found for fatal or disabling stroke (3.5 versus 6.1 percent) and for fatal stroke alone (2.1 versus 4.2 percent). About one-half of the strokes in the trial were fatal or disabling (",
"      <a class=\"graphic graphic_figure graphicRef64869 \" href=\"UTD.htm?29/25/30109\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The ACST subgroup analyses reported the results of risk reduction for nonperioperative stroke (ie, the benefit) separately from the perioperative risk (ie, the risk), but did not report the overall balance of benefit and risk, which is of most importance to patients and clinicians [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/14\">",
"       14",
"      </a>",
"      ]. The benefit of CEA for preventing nonperioperative stroke was separately significant for men and women in the subgroup analysis. The absolute risk reduction over five years was greater for men than for women (8.2 percent [95% CI 5.64-10.78] versus 4.08 percent [95% CI 0.74-7.41]). This difference was attributed to the smaller number of women enrolled. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Gender'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The benefit from CEA was statistically significant for patients younger than 75 years of age. Only 650 patients in the trial were aged 75 or older, and the benefit was uncertain for that group.",
"     </li>",
"     <li>",
"      The benefit of CEA was statistically significant for contralateral as well as ipsilateral carotid strokes; this finding was not attributable to any substantial difference in the use of contralateral CEA. The benefit for ipsilateral and contralateral stroke reduction was independent of any history of contralateral occlusion or symptoms. The investigators speculated that collateral arterial flow via the Circle of Willis might be the mechanism for contralateral stroke risk reduction from ipsilateral CEA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of CEA was maintained at long-term follow-up (median nine years) in the ACST cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/12\">",
"     12",
"    </a>",
"    ]. The net risk for all stroke or perioperative death in the immediate CEA group was significantly reduced compared with the CEA deferral group at both five years (6.9 versus 10.9 percent) and 10 years (13.4 versus 17.9 percent).",
"   </p>",
"   <p>",
"    Despite the relatively low 30-day perioperative risk in ACST (3 percent), the net benefit of CEA was delayed for about two years after surgery (",
"    <a class=\"graphic graphic_figure graphicRef51041 \" href=\"UTD.htm?33/23/34173\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. That is, the immediate CEA group had a worse event-free survival compared with the delayed group until just prior to two years after surgery, when the immediate CEA group first began to show a better outcome. In contrast, the NASCET trial for patients with symptomatic carotid stenosis showed that the benefits of CEA began accruing much earlier (",
"    <a class=\"graphic graphic_figure graphicRef75669 \" href=\"UTD.htm?16/50/17197\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67964 \" href=\"UTD.htm?16/58/17325\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'NASCET trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like the ACAS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/2\">",
"     2",
"    </a>",
"    ], the degree of carotid stenosis did not significantly affect the benefit from CEA in ACST; the benefit for patients with about 70 percent carotid stenosis was similar to that for patients with 80 or 90 percent carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. In contrast, the major symptomatic carotid surgery trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/15-17\">",
"     15-17",
"    </a>",
"    ] found greater benefit for patients with higher degrees of stenosis. The reason for this discrepancy is unclear; failure to detect the relevance of the degree of stenosis in the asymptomatic trials might reflect the imperfections of ultrasound as a sole technique of measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional subgroup analyses in ACST found no significant impact on benefit for CEA related to systolic blood pressure above or below 160 mmHg, plaque echolucency, diabetes, or ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Delay to benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEA for patients with asymptomatic carotid atherosclerosis is a long-term investment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ]. The ACAS and especially the ACST trials showed that the net benefit of CEA is delayed, as the asymptomatic population has an overall worse outcome after CEA for many months to nearly two years because of perioperative morbidity. Significant benefit does not accrue until approximately two years or more after surgery. Early after CEA, perioperative morbidity outweighs the modest (though significant) reduction in stroke risk that accrues following the procedure. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'ACAS trial'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'ACST trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perioperative complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEA for patients with asymptomatic carotid atherosclerosis should be performed only at institutions where the perioperative stroke and death rate are &lt;3 percent. The rationale is that combined morbidity and mortality that exceed 3 percent could eliminate the benefit gained from surgery for patients with asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Surgeons participating in the ACAS trial were required to have a perioperative complication rate of &lt;3 percent in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, the ACST reported a 3.1 percent perioperative complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'ACAS trial'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'ACST trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Even relatively small increases in major surgical and angiographic complication rates may tip the balance against CEA for patients with asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the utility of this information is limited in practice, since it may be difficult to obtain the appropriate perioperative complication rates for individual surgeons or centers.",
"   </p>",
"   <p>",
"    A review of Medicare recipients undergoing CEA found a higher mortality rate in hospitals that did not participate in major carotid surgery trials, particularly in those centers performing fewer procedures (2.9 percent, versus 1.4 percent in NASCET and ACAS trial hospitals) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/22\">",
"     22",
"    </a>",
"    ]. Low patient volume (less than three CEAs performed every two years) and a greater number of years since licensure of the surgeon have also been associated with worse outcomes following CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'NASCET trial'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'ACAS trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factors influencing benefit and risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors may influence the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio with endarterectomy and thus the decision to treat individual patients with asymptomatic carotid occlusive disease. Risk factors for morbidity and mortality associated with endarterectomy should be identified in order to avoid surgery in those who may face unacceptably high surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/24\">",
"     24",
"    </a>",
"    ]. These risk factors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H5#H5\">",
"     \"Carotid endarterectomy\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are unlikely to benefit from CEA include those who have severe comorbidity due to other medical or surgical illness, patients with a prior ipsilateral stroke associated with persistent disabling neurologic deficits, and patients with total occlusion of the internal carotid artery.",
"   </p>",
"   <p>",
"    The impact of advances in medical therapy on the relative benefit of CEA for asymptomatic carotid disease is discussed below. (See",
"    <a class=\"local\" href=\"#H10308274\">",
"     'Medical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other factors that may influence the benefit and risk of CEA for patients with asymptomatic carotid stenosis include patient gender, the presence of contralateral carotid stenosis or occlusion, ischemic stroke heterogeneity, the risk of unheralded carotid stroke (without transient ischemic attack), and the progression of asymptomatic carotid stenosis. This section will discuss these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of CEA appears to be greater for men than for women with asymptomatic carotid disease. Furthermore, it is unclear if women with this condition benefit from CEA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of data from the ACAS and ACST trials (",
"      <a class=\"graphic graphic_figure graphicRef80838 \" href=\"UTD.htm?10/37/10846\">",
"       figure 7",
"      </a>",
"      ) found no benefit for women with respect to the five-year risk of any stroke or perioperative death (odds ratio [OR] 0.96, 95% CI 0.63-1.45) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/14\">",
"       14",
"      </a>",
"      ]. In contrast, there was statistically significant benefit for men (OR 0.49, 95% CI 0.36-0.66).",
"     </li>",
"     <li>",
"      In the ACST trial, the benefit of surgery for women with asymptomatic carotid disease was reported as statistically significant, although less robust than the benefit for men [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"       3",
"      </a>",
"      ]. However, this analysis excluded perioperative events. The overall balance of benefit and risk (including perioperative events), which is of most importance to patients and clinicians, was not reported. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ACST trial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Asymptomatic embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence from observational studies suggests that asymptomatic cerebral embolism, detected by transcranial Doppler (TCD) ultrasound, is associated with an increased risk of ischemic stroke in patients with asymptomatic carotid atherosclerotic occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the prospective multicenter ACES study of 467 patients with asymptomatic carotid stenosis of &ge;70 percent, patients with embolic signals on baseline TCD (n = 77) had a significantly increased rate of ipsilateral stroke or TIA at two years (the primary endpoint) compared with patients who had no embolic signals (13 versus 6 percent, hazard ratio [HR] 2.5, 95% CI 1.2-5.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/25\">",
"       25",
"      </a>",
"      ]. In addition, patients with embolic signals on baseline TCD had a significantly increased risk of ipsilateral stroke alone (HR 5.6, 95% CI 1.6-10.3).",
"     </li>",
"     <li>",
"      In a meta-analysis of six reports, with data available for 1144 patients with asymptomatic carotid disease, including 467 from ACES, patients with embolic signals present had a significantly higher risk of ipsilateral stroke (HR 6.6, 95% CI 2.9-15.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective study from a single tertiary center enrolled 468 patients with asymptomatic carotid stenosis of &ge;60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/26\">",
"       26",
"      </a>",
"      ]. At two years, patients with microemboli on baseline TCD (n = 37) had a significantly higher rate of the composite cardiovascular endpoint of stroke, death, myocardial infarction, or CEA after development of symptoms (32 versus 9 percent of those without microemboli).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data imply that detection of cerebral emboli by TCD might be used to identify patients with asymptomatic carotid occlusive disease who are at high and low risk of stroke, and thus to help select those most likely to benefit or not from treatment with CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the utility of this approach requires further study. Dual antiplatelet therapy is under investigation as another way to reduce cerebral embolism from large artery disease, but it remains unproven whether this method would lead to improved clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Aspirin plus clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371860508\">",
"    <span class=\"h3\">",
"     Carotid plaque morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that plaque morphology on carotid ultrasound is a useful measure of stroke risk for patients with asymptomatic carotid stenosis. In one report of 253 patients with asymptomatic carotid stenosis, both right and left carotid arteries were scanned with 3D ultrasound, and the risk of stroke or death was significantly higher for patients with three or more carotid ulcers compared with those who had less than three ulcers (18 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/27\">",
"     27",
"    </a>",
"    ]. In another report of 435 patients with asymptomatic carotid stenosis, echolucent plaques were independently associated with an increased risk of ipsilateral stroke even after controlling for the presence of embolic signals at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/28\">",
"     28",
"    </a>",
"    ]. However, low event numbers in these studies preclude firm conclusions.",
"   </p>",
"   <p>",
"    As with emboli detection, these data imply that ultrasound determination of carotid plaque morphology might someday be useful to identify patients with asymptomatic carotid occlusive disease who are at high risk of stroke and therefore likely to benefit from carotid revascularization. This approach too requires additional study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Contralateral carotid stenosis or occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The status of the contralateral carotid artery may have an impact upon outcome after CEA. A subgroup analysis of the ACAS study found that CEA in patients with a complete occlusion of the contralateral carotid artery provided no long-term benefit in terms of preventing stroke or death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/29\">",
"     29",
"    </a>",
"    ]. With regard to five-year ipsilateral stroke risk, CEA resulted in a better outcome for the 737 patients without contralateral occlusion compared with medical therapy (6.7 percent risk reduction, 95% CI 2.1 to 11.4), but no benefit for the 86 patients with contralateral carotid occlusion (2.0 percent increase, 95% CI -9.3 to 5.2). The difference was primarily attributable to a low long-term risk for medically treated patients with contralateral occlusion. This finding requires confirmation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'ACAS trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Stroke heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of the NASCET cohort suggested that the benefits of CEA in asymptomatic patients may be overestimated, since a number of strokes that occur in the territory of stenotic arteries are not preventable by CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/30\">",
"     30",
"    </a>",
"    ]. This study followed over 1800 patients to determine the causes, severity, risk, and predictors of stroke in the territory of the asymptomatic artery. Approximately one-half of strokes were cardioembolic or lacunar in origin, which are not preventable by CEA (",
"    <a class=\"graphic graphic_figure graphicRef50809 \" href=\"UTD.htm?32/42/33453\">",
"     figure 8",
"    </a>",
"    ). The risk of preventable large artery stroke increased with higher degrees of carotid stenosis, a history of diabetes, and the presence of silent infarction beyond the asymptomatic lesion. As expected, the risk of stroke over five years of follow-up was higher in patients with 60 to 99 percent stenosis compared with those with &lt;60 percent stenosis in the asymptomatic artery (16 versus 8 percent).",
"   </p>",
"   <p>",
"    The investigators calculated that using only large artery strokes as measures of outcome would diminish the benefit of CEA: the absolute reduction (ARR) in stroke with CEA would decrease from 5.9 percent found in the ACAS trial to 3.5 percent, while the number of patients needed to treat to prevent a stroke would almost double [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/30\">",
"     30",
"    </a>",
"    ]. The authors concluded that this finding \"tips the scales\" against the routine use of CEA in asymptomatic patients.",
"   </p>",
"   <p>",
"    Not all experts agree with their conclusion, citing concerns that many strokes due to extracranial carotid atherothrombosis occur without warning (eg, a TIA), that natural history studies show an increased rate of stroke in patients with asymptomatic carotid stenosis of &ge;75 percent, and that in NASCET, increasing degrees of stenosis were associated with higher rates of stroke and greater benefit from CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, it seems reasonable that patients with asymptomatic severe carotid stenosis be fully evaluated for other treatable causes of stroke because of the frequent coexistence of multiple potential etiologies for ischemic stroke in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Unheralded carotid stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with asymptomatic carotid disease, natural history studies suggest that the majority of strokes caused by carotid artery atherosclerosis are preceded by TIA and that the incidence of unheralded stroke (ie, not preceded by TIA) from carotid disease is relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/33\">",
"     33",
"    </a>",
"    ]. Transient ischemic attacks occurred in nearly 70 percent of patients as the qualifying event for entry in the NASCET cohort, and observational data suggest that ischemic stroke due to extracranial carotid disease is preceded by TIA in 50 to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts have argued that this evidence supports a conservative approach to CEA in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/33,37\">",
"     33,37",
"    </a>",
"    ]; TIA occurrence in previously asymptomatic patients may serve as a warning to allow an opportunity to intervene with CEA and prevent disabling stroke, while avoiding operative risk in those who remain asymptomatic. From another perspective, however, the rate of unheralded stroke ipsilateral to an asymptomatic but hemodynamically significant extracranial carotid artery stenosis is about 1 to 2 percent annually [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/30,32,38,39\">",
"     30,32,38,39",
"    </a>",
"    ], a rate that represents a large incidence on a population basis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/32\">",
"     32",
"    </a>",
"    ]. This perspective has been used to support a more aggressive approach to CEA in asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Degree of stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major symptomatic CEA trials have consistently found increased risk of stroke with higher degrees of stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the data regarding degree of stenosis and stroke risk in asymptomatic carotid disease are conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major asymptomatic CEA trials (ACAS and ACST) have not found a correlation between degree of stenosis and risk of stroke for patients with asymptomatic 60 to 99 percent stenosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'ACAS trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'ACST trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several natural history studies have reported that an increasing degree of asymptomatic carotid stenosis is associated with an increased stroke risk [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/37,38,40-44\">",
"       37,38,40-44",
"      </a>",
"      ]. As an example, one study analyzed the natural history of asymptomatic carotid disease in 714 patients who had serial carotid ultrasound examinations biannually for a mean follow-up of 3.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/44\">",
"       44",
"      </a>",
"      ]. Progression to carotid stenosis of &ge;80 percent was associated with a significantly higher risk for cerebrovascular events and death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These latter data would seem to support the use of CEA for asymptomatic carotid disease, particularly as the degree of carotid stenosis approaches hemodynamic significance, which is generally thought to be a stenosis greater than 70 to 75 percent or a residual lumen diameter of 1.5 mm or less [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/31,45,46\">",
"     31,45,46",
"    </a>",
"    ]. However, this approach (selecting asymptomatic patients for CEA based upon degree of stenosis) requires confirmation from randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CAROTID STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery angioplasty and stenting (CAS) is an alternative to carotid endarterectomy (CEA) for the treatment of patients with carotid atherosclerotic disease, particularly in patients considered to be poor candidates for surgery. However, there are conflicting data regarding the notion that patients with a high risk of poor outcome after CEA can be reliably identified, and the very existence of such a group of high-risk of patients has been challenged. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838506#H93838506\">",
"     \"Carotid endarterectomy\", section on 'Perioperative risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endarterectomy remains the preferred treatment for most patients with symptomatic carotid atherosclerosis who have standard surgical risk. Nevertheless, accumulating evidence suggest that CAS and CEA provide similar long-term outcomes for patients with asymptomatic and symptomatic carotid occlusive disease, while the periprocedural risk of stroke and death may be higher with CAS. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Stenting trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the available data discussed below, we suggest not treating asymptomatic carotid disease with CAS unless in the context of a clinical trial in centers with demonstrated low (&lt;3 percent) periprocedural risk.",
"   </p>",
"   <p>",
"    Risk factors for periprocedural complications of CAS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link\">",
"     \"Carotid artery stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stenting trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;No high-quality randomized controlled trials comparing CEA with CAS have focused exclusively on patients with asymptomatic carotid disease. However, in the SAPPHIRE and CREST trials discussed below, nearly one-half or more of the included patients had asymptomatic disease.",
"   </p>",
"   <p>",
"    Although definitive data are lacking, the available evidence suggests that the periprocedural (30 day) stroke or death rate is higher with CAS than with CEA, while the risk of stroke or death beyond 30 days is similar for both techniques.",
"   </p>",
"   <p>",
"    A Cochrane systematic review identified ten randomized controlled trials with 3178 patients published by March 2007 that compared CEA with CAS in patients with symptomatic or asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/47\">",
"     47",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis, the primary outcome measure of any stroke or death at 30 days favored CEA using a fixed-effects model, but the result did not achieve statistical significance using the random effects model, which is less likely to underestimate confidence intervals. Two trials with 136 patients studied asymptomatic carotid disease only, and an analysis of these found no difference between CEA and CAS for the combined endpoint of any stroke or death within 30 days. However, small patient numbers limit the strength of this analysis.",
"     </li>",
"     <li>",
"      During long-term follow-up, the overall analysis found no significant difference between CEA and CAS in the risk of stroke or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These meta-analysis data were difficult to interpret because confidence intervals were wide, substantial heterogeneity existed among the trials, and several of the trials were stopped early [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, the reviewers concluded that there was insufficient evidence to support a move away from recommending CEA as the treatment of choice for suitable carotid stenosis.",
"   </p>",
"   <p>",
"    Trials comparing CEA with CAS for exclusively symptomatic carotid disease are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     CREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CREST trial randomly assigned 2502 patients with carotid atherosclerotic disease to endarterectomy or stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/48\">",
"     48",
"    </a>",
"    ]. The proportion of enrolled patients with asymptomatic and symptomatic carotid disease was 47 and 53 percent, respectively. The overall effectiveness and safety of the two procedures (CAS and CEA) were similar, and the benefits were equal for men and women and for patients with asymptomatic and symptomatic carotid disease. The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoint for the trial, a composite of any stroke, MI, or death within 30 days following treatment plus any ipsilateral stroke during long-term follow-up (median 2.5 years), was similar for stenting and endarterectomy (7.2 versus 6.8 percent, hazard ratio [HR] 1.1, 95% CI 0.8-1.5).",
"     </li>",
"     <li>",
"      The rate of ipsilateral stroke occurring from 31 days post-procedure to four years of follow-up was also similar for stenting and endarterectomy (2.0 versus 2.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, some important differences emerged [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients age 70 and older, the rate of the primary endpoint and adverse events increasingly favored surgery over stenting. As a result, CAS tended to have greater benefit at younger ages, while endarterectomy tended to have greater benefit at older ages [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proportion of patients with stroke within 30 days of the procedure was significantly higher in the stenting than the endarterectomy group (4.1 versus 2.3 percent, HR 1.8, 95% CI 1.1-2.8).",
"     </li>",
"     <li>",
"      The frequency of myocardial infarction within 30 days of the procedure was significantly lower in the stenting group (1.1 percent versus 2.3 percent, HR 0.5, 95% CI 0.3-0.9).",
"     </li>",
"     <li>",
"      At one year after the procedure, quality of life was significantly diminished for patients who developed stroke, even a minor stroke, compared with those who developed myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/48\">",
"       48",
"      </a>",
"      ]. A CREST substudy found that at one year, stroke had a large and statistically significant detrimental impact on quality of life, while both myocardial infarction and cranial nerve palsy had small impacts on quality of life that were",
"      <strong>",
"       not",
"      </strong>",
"      statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/49\">",
"       49",
"      </a>",
"      ]. However, despite the higher rate of stroke with stenting, there were no significant differences at one year after the procedure between the CEA and CAS groups in any quality of life measure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     SAPPHIRE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SAPPHIRE trial tested the hypothesis that CAS is not inferior to CEA in patients considered at high risk for carotid surgery who had either symptomatic or asymptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The surgical investigators decided which patients were suitable for surgery or randomization, and patients judged to have unacceptable risk for endarterectomy were allowed entry into a stent registry.",
"   </p>",
"   <p>",
"    SAPPHIRE randomly assigned 334 patients to either CAS or CEA; both symptomatic patients with &ge;50 percent carotid stenosis and asymptomatic patients with &ge;80 percent carotid stenosis by angiography or ultrasound were enrolled. More than 70 percent of patients had asymptomatic carotid disease. The stent used employed a distal embolic protection device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H4#H4\">",
"     \"Carotid artery stenting and its complications\", section on 'Embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At one year, CAS was not inferior to CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/51\">",
"     51",
"    </a>",
"    ]. The primary end point of SAPPHIRE was the cumulative incidence of a major cardiovascular event at one year, which included a composite of periprocedural death, stroke, or myocardial infarction (within 30 days after the procedure),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death or ipsilateral stroke between 31 days and one year. There was an almost significant reduction in the primary composite end point for CAS compared with CEA (12.2 versus 20.1 percent, absolute difference 7.9 percent, 95% CI -0.7 to 16.4 percent). At three years, a statistical comparison for noninferiority was not specified, and follow-up was incomplete, with data available for only 78 percent of the subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/53\">",
"     53",
"    </a>",
"    ]. There was no significant difference in the major secondary end point (ie, primary end point events plus death or ipsilateral stroke between one and three years) for CAS compared with CEA (24.6 versus 26.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of methodologic and statistical problems with SAPPHIRE have made the conclusions problematic and controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/24,54-57\">",
"     24,54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An obvious bias favoring stenting in the SAPPHIRE study was the inclusion of substantial numbers of patients (more than 20 percent in each treatment group) with recurrent carotid artery stenosis. This bias favored the CAS group, since complication rates are higher with repeat or \"redo\" CEA than with primary CEA. In addition, the risk of embolization is lower with CAS for intimal hyperplasia (a common cause of restenosis) than it is with CAS for complex plaque due to atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The composite end point included myocardial infarction, an end point that was not included in the major randomized trials of CEA versus medical therapy. The trend toward a better outcome at one year for the CAS treatment group in the composite end point compared with CEA was largely due to the higher incidence of perioperative myocardial infarction in the CEA group [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/54,56\">",
"       54,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients enrolled in SAPPHIRE were at high risk for surgery, and the outcomes for both the CAS and CEA treatment groups were poor, much worse than for NASCET or the other major trials of CEA for symptomatic or asymptomatic disease. In addition, the periprocedural complication rates in both the CAS and CEA treatment groups were higher than the 3 percent rate recommended in current guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]; a complication rate higher than 3 percent may negate any potential advantages of carotid stenting. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Perioperative complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these shortcomings, the conclusion that CAS is not inferior to CEA in patients with asymptomatic disease is probably valid for the patient group that was studied, that is, those considered \"high risk\" because of severe cardiac or pulmonary disease, contralateral carotid occlusion, prior neck surgery or neck irradiation, contralateral laryngeal nerve palsy, recurrent stenosis after CEA, and age &gt;80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the SAPPHIRE trial design and methodology does not permit definitive conclusions regarding the equivalence or superiority of CAS compared with CEA in high or moderate-risk surgical patients, the United States Food and Drug Administration (FDA) granted approval for the stent device and protection device used in SAPPHIRE only for high-risk patients with",
"    <strong>",
"     symptomatic",
"    </strong>",
"    carotid artery stenosis.",
"   </p>",
"   <p>",
"    The SAPPHIRE trial also raises the untested possibility that modern medical management with antiplatelet drugs and statins might be superior to stenting or surgery for such high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10308274\">",
"     'Medical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Stenting in specific subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients appear to do worse with CAS than with CEA, even though old age was originally proposed to be a condition associated with high surgical risk and therefore a potential indication for stenting rather than endarterectomy. The following observations address this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the prospective CREST trial, the rate of poor outcome in patients age 70 and older was higher with stenting than with endarterectomy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'CREST'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a meta-analysis of 41 studies of either CEA or CAS in patients &ge;80 years old, the relative risks of death or myocardial infarction at 30 days were similar for patients having CAS and CEA, but the stroke rate was significantly higher for CAS (7.0 versus 1.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/58\">",
"       58",
"      </a>",
"      ]. Based upon an acceptable 3 percent stroke rate at 30 days, the pooled relative risk (RR) was more than three-fold higher for stroke after CAS (RR 2.18 versus 0.63 with CEA). Most of the included studies were retrospective, so the results of this meta-analysis are not definitive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In data drawn largely from registries and case series, subgroups suggested to have tolerated CAS with relative safety included patients with prior neck irradiation, high cervical carotid bifurcations, and those with complete occlusion of the contralateral internal carotid artery. Further evidence from large controlled clinical trials is needed before drawing firm conclusions about the safety and effectiveness of CAS in these various subgroups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H101621741#H101621741\">",
"     \"Carotid artery stenting and its complications\", section on 'Risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10308274\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern medical therapy that includes rigorous and compliant use of statins and antiplatelet agents, along with treatment of hypertension, cigarette smoking, and diabetes, has probably narrowed the gap between medical and surgical treatment of carotid disease for reducing the risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Thus, intensive medical management may be a reasonable alternative to endarterectomy in patients with asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From the late 1980s through the mid 1990s, the period when most of the major endarterectomy trials were underway, the best medical therapy for carotid disease was generally considered to be antiplatelet treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . However, since the completion of these trials, newer medical regimens have emerged that reduce the risk of stroke and cardiovascular events, including the more widespread and aggressive use of statins, antiplatelet agents, and antihypertensive agents, along with a reduction in the prevalence of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvements in medical therapy would diminish the relative risk reduction afforded by CEA for carotid disease and increase the number of patients needed to treat with CEA to prevent one stroke. This issue is particularly important for patients with asymptomatic carotid disease, in whom the number needed to treat is already high compared with symptomatic patients.",
"   </p>",
"   <p>",
"    Some insight into the changes in medical therapy over the years comes from the ACST trial, which began about a decade after the other major endarterectomy trials. In ACST, the use of lipid lowering drugs rose dramatically over the 10-year course of patient enrollment, from 17 percent in earlier randomization (1993 to 1996) to 58 percent in later randomization (2000 to 2003) (",
"    <a class=\"graphic graphic_figure graphicRef76660 \" href=\"UTD.htm?34/35/35389\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"     3",
"    </a>",
"    ]. A 2004 survey of ACST collaborators indicated that routine lipid lowering therapy would rise to at least 90 percent. Antihypertensive and antiplatelet drug use in ACST was widespread throughout the trial and also increased after randomization. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'ACST trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some experts argue that modern medical treatment is now as effective as revascularization with CEA or CAS for reducing stroke risk in patients with asymptomatic carotid disease. The following observations support this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of prospective data from 11 studies found that the average annual rates of ipsilateral and any-territory ischemic stroke have fallen significantly since the mid-1980s in patients with asymptomatic severe carotid stenosis assigned to medical intervention alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/60\">",
"       60",
"      </a>",
"      ]. The stroke rates for medically treated patients are now estimated to overlap those reported for patients who had CEA for asymptomatic disease in the major randomized trials such as the VA, ACAS, and ACST trials. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endarterectomy trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A prospective population-based study identified 101 patients with an asymptomatic &ge;50 percent carotid stenosis who were treated with intensive medical management. Over a mean follow-up of three years, there was only one minor ipsilateral stroke, for an average annual stroke rate of 0.34 percent (95% CI 0.1-1.87) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/62\">",
"       62",
"      </a>",
"      ]. By comparison, ipsilateral annual stroke rates in patients assigned to medical therapy in the major endarterectomy trials were approximately 2 to 3 percent. However, small patient numbers limit the strength of this study.",
"     </li>",
"     <li>",
"      A prospective study from a single tertiary center compared treatment and outcome for two groups of patients with asymptomatic carotid stenosis of &ge;60 percent: 199 patients who were enrolled from 2000 through 2002 (designated \"before 2003\") and 269 patients who were enrolled from 2003 through 2007 (designated \"since 2003\") [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/26\">",
"       26",
"      </a>",
"      ]. The year 2003 was chosen as the cut point because the center by 2003 had implemented a change to intensive medical therapy for patients with accelerated atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/63\">",
"       63",
"      </a>",
"      ]. Compared with the \"before 2003\" group, the \"since 2003\" group showed the following statistically significant improved outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/26\">",
"       26",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At baseline, a reduction in the proportion of patients with intracranial microemboli detected by transcranial Doppler ultrasound (12.6 versus 3.7 percent)",
"     </li>",
"     <li>",
"      A lower rate of carotid plaque progression in the first year of follow-up (23 mm",
"      <sup>",
"       2",
"      </sup>",
"      , versus 69 mm",
"      <sup>",
"       2",
"      </sup>",
"      at baseline)",
"     </li>",
"     <li>",
"      In the first two years of follow-up, a decrease in the composite cardiovascular event endpoint of stroke, death, myocardial infarction, or CEA after development of symptoms (17.6 versus 5.6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these reports suggest that modern medical treatment is as effective as CEA for the prevention of stroke in patients with asymptomatic carotid disease, they involve cross-study comparisons that may introduce bias. In addition, they do not allow for the possibility that improvements in surgical technique since the mid-1980s have led to greater stroke risk reduction with endarterectomy. Ideally, the effectiveness of intensive modern medical management versus CEA should be confirmed in a randomized controlled trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PRACTICE GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the primary prevention of stroke issued in 2011 by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    made the following recommendations regarding the management of asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asymptomatic carotid artery stenosis should be screened for other treatable risk factors for stroke with institution of appropriate lifestyle changes and medical therapy.",
"     </li>",
"     <li>",
"      Selection of asymptomatic patients for carotid revascularization should be guided by an assessment of comorbid conditions and life expectancy, as well as other individual factors, and should include a thorough discussion of the risks and benefits of the procedure with an understanding of patient preferences.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in conjunction with CEA is recommended unless contraindicated.",
"     </li>",
"     <li>",
"      Prophylactic CEA performed with &lt;3 percent morbidity and mortality can be useful in highly selected patients with an asymptomatic carotid stenosis (minimum 60 percent by angiography, 70 percent by validated Doppler ultrasound). It should be noted that the benefit of surgery may now be lower than anticipated based on randomized trial results, and the cited 3 percent threshold for complication rates may be high because of interim advances in medical therapy.",
"     </li>",
"     <li>",
"      Prophylactic CAS might be considered in highly selected patients with an asymptomatic carotid stenosis (&ge;60 percent on angiography, &ge;70 percent on validated Doppler ultrasonography, or &ge;80 percent on CT angiography or MR angiography if the stenosis on ultrasonography was 50 to 69 percent). The advantage of revascularization over current medical therapy alone is not well established.",
"     </li>",
"     <li>",
"      The usefulness of CAS as an alternative to CEA in asymptomatic patients at high risk for the surgical procedure is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multispecialty guidelines for the management of extracranial carotid and vertebral artery disease published in 2011 are concordant with the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines with respect to asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, guidelines from the Society for Vascular surgery recommend CEA as first-line treatment for most patients with asymptomatic carotid stenosis of 60 to 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/6\">",
"     6",
"    </a>",
"    ]. These guidelines state that CAS is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for patients with asymptomatic carotid stenosis.",
"   </p>",
"   <p>",
"    All these guidelines note that the advantage of revascularization with CAS for patients with asymptomatic carotid disease over current medical therapy alone is not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, the reality of current practice, at least up to 2007, is that both CEA and CAS are most often performed for",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    rather than",
"    <strong>",
"     symptomatic",
"    </strong>",
"    carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. It is likely that this situation still persists despite the reimbursement policy in the United States of the Centers for Medicare and Medicaid Services, which covers CAS outside of trials for patients considered high risk for CEA who have symptomatic severe (&ge;70 percent) carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/67\">",
"     67",
"    </a>",
"    ]. The policy also covers CAS when used in post-approval studies or in clinical trials for patients at high risk for CEA with symptomatic carotid stenosis of 50 to 70 percent or asymptomatic carotid stenosis that is &ge;80 percent. This reimbursement policy was not changed by the May 2011 regulatory decision to approve the RX Acculink carotid stent device in the US for patients who are not at high risk, including those who are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/33/16922/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       \"Patient information: Carotid artery disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"       \"Patient information: Atherosclerosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid endarterectomy (CEA) is beneficial for patients with",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      extracranial internal carotid artery stenosis of 60 to 99 percent. However, the number needed to treat to prevent one stroke at three years is about 33, and the degree of benefit is not as great as it is for",
"      <strong>",
"       symptomatic",
"      </strong>",
"      carotid stenosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endarterectomy trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest CEA rather than medical treatment alone for medically stable men with asymptomatic carotid stenosis of 60 to 99 percent who have a life expectancy of at least five years, provided the combined perioperative risk of stroke and death is less than 3 percent for the surgeon and center (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation places a relatively high value on longer-term stroke prevention and a relatively lower value on avoidance of short-term perioperative stroke and death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors influencing benefit and risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CEA in asymptomatic patients should be considered a long-term investment, as the benefit of CEA for asymptomatic disease emerges only after a number of years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Delay to benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors may influence the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio with endarterectomy and thus the decision to treat individual patients with asymptomatic carotid occlusive disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Risk factors for morbidity and mortality associated with endarterectomy should be identified in order to avoid surgery in those who may face unacceptably high surgical risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838506#H93838506\">",
"       \"Carotid endarterectomy\", section on 'Perioperative risk assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are unlikely to benefit from CEA include those who have severe comorbidity due to other medical or surgical illness, patients with a prior ipsilateral stroke associated with persistent disabling neurologic deficits, and patients with total occlusion of the internal carotid artery. Other factors that may influence the benefit and risk of CEA for patients with asymptomatic carotid stenosis include patient gender, the presence of contralateral carotid stenosis or occlusion, ischemic stroke heterogeneity, the risk of unheralded carotid stroke (without transient ischemic attack), and the progression of asymptomatic carotid stenosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors influencing benefit and risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evidence supporting CEA for the treatment of asymptomatic carotid disease is less compelling for women than for men, and a meta-analysis of the ACAS and ACST trial data showed",
"      <strong>",
"       no",
"      </strong>",
"      benefit for women. We suggest medical management rather than CEA for women with asymptomatic carotid stenosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, this issue is controversial, and some experts favor CEA for both women and men with asymptomatic high-grade carotid stenosis. Thus, for women with asymptomatic carotid stenosis of 60 to 99 percent (or more conservatively, 70 to 99 percent as favored by other experts) who have a life expectancy of at least five years, CEA is a reasonable alternative to medical management provided the combined perioperative risk of stroke and death is less than 3 percent for the surgeon and center. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors influencing benefit and risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accumulating evidence suggests that both carotid artery angioplasty and stenting (CAS) and CEA provide similar long-term outcomes for patients with asymptomatic and symptomatic carotid occlusive disease. However, the periprocedural risk of stroke and death may be higher with CAS. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating asymptomatic carotid artery stenosis with CAS unless it is performed in the context of a clinical trial in centers with demonstrated low (&lt; 3 percent) periprocedural risk for combined stroke and death (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Carotid stenting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modern medical therapy that includes that rigorous and compliant use of statins and antiplatelet agents, along with treatment of hypertension, cigarette smoking, and diabetes, has probably narrowed the gap between medical and surgical treatment of carotid disease for reducing the risk of stroke. Thus, medical management may be a reasonable alternative to CEA in patients with asymptomatic carotid disease. (See",
"      <a class=\"local\" href=\"#H10308274\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/1\">",
"      Hobson RW 2nd, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med 1993; 328:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/2\">",
"      Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/3\">",
"      Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/4\">",
"      Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/5\">",
"      Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011; 42:e464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/6\">",
"      Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg 2011; 54:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/7\">",
"      Schneider PA, Naylor AR. Asymptomatic carotid artery stenosis--medical therapy alone versus medical therapy plus carotid endarterectomy or stenting. J Vasc Surg 2010; 52:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/8\">",
"      Jayasooriya GS, Shalhoub J, Thapar A, Davies AH. Patient preference survey in the management of asymptomatic carotid stenosis. J Vasc Surg 2011; 53:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/9\">",
"      Klein A, Solomon CG, Hamel MB. Clinical decisions. Management of carotid stenosis--polling results. N Engl J Med 2008; 358:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/10\">",
"      Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2005; :CD001923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/11\">",
"      Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/12\">",
"      Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/13\">",
"      Barnett HJ. Carotid endarterectomy. Lancet 2004; 363:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/14\">",
"      Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke 2004; 35:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/15\">",
"      Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/16\">",
"      Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/17\">",
"      Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/18\">",
"      Gorelick PB. Carotid endarterectomy : where do we draw the line? Stroke 1999; 30:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/19\">",
"      Goldstein LB, Moore WS, Robertson JT, Chaturvedi S. Complication rates for carotid endarterectomy. A call to action. Stroke 1997; 28:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/20\">",
"      Barnett HJ. The inappropriate use of carotid endarterectomy. CMAJ 2004; 171:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/21\">",
"      Moore WS, Vescera CL, Robertson JT, et al. Selection process for surgeons in the Asymptomatic Carotid Atherosclerosis Study. Stroke 1991; 22:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/22\">",
"      Wennberg DE, Lucas FL, Birkmeyer JD, et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. JAMA 1998; 279:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/23\">",
"      O'Neill L, Lanska DJ, Hartz A. Surgeon characteristics associated with mortality and morbidity following carotid endarterectomy. Neurology 2000; 55:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/24\">",
"      Brott TG, Brown RD Jr, Meyer FB, et al. Carotid revascularization for prevention of stroke: carotid endarterectomy and carotid artery stenting. Mayo Clin Proc 2004; 79:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/25\">",
"      Markus HS, King A, Shipley M, et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol 2010; 9:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/26\">",
"      Spence JD, Coates V, Li H, et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol 2010; 67:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/27\">",
"      Madani A, Beletsky V, Tamayo A, et al. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound vs TCD microemboli. Neurology 2011; 77:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/28\">",
"      Topakian R, King A, Kwon SU, et al. Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neurology 2011; 77:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/29\">",
"      Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators. Stroke 2000; 31:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/30\">",
"      Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 2000; 342:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/31\">",
"      Kistler JP, Furie KL. Carotid endarterectomy revisited. N Engl J Med 2000; 342:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/32\">",
"      Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/33\">",
"      Dodick DW, Meissner I, Meyer FB, Cloft HJ. Evaluation and management of asymptomatic carotid artery stenosis. Mayo Clin Proc 2004; 79:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/34\">",
"      Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. N Engl J Med 1977; 296:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/35\">",
"      Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/36\">",
"      Russo LS Jr. Carotid system transient ischemic attacks: clinical, racial, and angiographic correlations. Stroke 1981; 12:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/37\">",
"      Shanik GD, Moore DJ, Leahy A, et al. Asymptomatic carotid stenosis: a benign lesion? Eur J Vasc Surg 1992; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/38\">",
"      Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986; 315:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/39\">",
"      Bogousslavsky J, Despland PA, Regli F. Asymptomatic tight stenosis of the internal carotid artery: long-term prognosis. Neurology 1986; 36:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/40\">",
"      Roederer GO, Langlois YE, Jager KA, et al. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke 1984; 15:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/41\">",
"      Autret A, Pourcelot L, Saudeau D, et al. Stroke risk in patients with carotid stenosis. Lancet 1987; 1:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/42\">",
"      Norris JW, Zhu CZ. Stroke risk and critical carotid stenosis. J Neurol Neurosurg Psychiatry 1990; 53:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/43\">",
"      Bock RW, Gray-Weale AC, Mock PA, et al. The natural history of asymptomatic carotid artery disease. J Vasc Surg 1993; 17:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/44\">",
"      Lewis RF, Abrahamowicz M, C&ocirc;t&eacute; R, Battista RN. Predictive power of duplex ultrasonography in asymptomatic carotid disease. Ann Intern Med 1997; 127:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/45\">",
"      Suwanwela N, Can U, Furie KL, et al. Carotid Doppler ultrasound criteria for internal carotid artery stenosis based on residual lumen diameter calculated from en bloc carotid endarterectomy specimens. Stroke 1996; 27:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/46\">",
"      Can U, Furie KL, Suwanwela N, et al. Transcranial Doppler ultrasound criteria for hemodynamically significant internal carotid artery stenosis based on residual lumen diameter calculated from en bloc endarterectomy specimens. Stroke 1997; 28:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/47\">",
"      Ederle J, Featherstone RL, Brown MM. Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review. Stroke 2009; 40:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/48\">",
"      Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/49\">",
"      Cohen DJ, Stolker JM, Wang K, et al. Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). J Am Coll Cardiol 2011; 58:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/50\">",
"      Voeks JH, Howard G, Roubin GS, et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke 2011; 42:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/51\">",
"      Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/52\">",
"      Yadav JS. Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial. Cleve Clin J Med 2004; 71 Suppl 1:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/53\">",
"      Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008; 358:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/54\">",
"      Cambria RP. Stenting for carotid-artery stenosis. N Engl J Med 2004; 351:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/55\">",
"      Thomas DJ. Protected carotid artery stenting versus endarterectomy in high-risk patients reflections from SAPPHIRE. Stroke 2005; 36:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/56\">",
"      LoGerfo FW. Carotid stents: unleashed, unproven. Circulation 2007; 116:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/57\">",
"      Samuelson RM, Yamamoto J, Levy EI, et al. The argument to support broader application of extracranial carotid artery stent technology. Circulation 2007; 116:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/58\">",
"      Usman AA, Tang GL, Eskandari MK. Metaanalysis of procedural stroke and death among octogenarians: carotid stenting versus carotid endarterectomy. J Am Coll Surg 2009; 208:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/59\">",
"      Woo K, Garg J, Hye RJ, Dilley RB. Contemporary results of carotid endarterectomy for asymptomatic carotid stenosis. Stroke 2010; 41:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/60\">",
"      Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40:e573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/61\">",
"      Spence JD. Asymptomatic carotid stenosis. Circulation 2013; 127:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/62\">",
"      Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 2010; 41:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/63\">",
"      Spence JD. Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. Curr Neurol Neurosci Rep 2007; 7:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/64\">",
"      Steppacher R, Csikesz N, Eslami M, et al. An analysis of carotid artery stenting procedures performed in New York and Florida (2005-2006): procedure indication, stroke rate, and mortality rate are equivalent for vascular surgeons and non-vascular surgeons. J Vasc Surg 2009; 49:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/65\">",
"      Eslami MH, McPhee JT, Simons JP, et al. National trends in utilization and postprocedure outcomes for carotid artery revascularization 2005 to 2007. J Vasc Surg 2011; 53:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/33/16922/abstract/66\">",
"      Berkowitz SA, Redberg RF. Dramatic increases in carotid stenting despite nonconclusive data. Arch Intern Med 2011; 171:1794.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid services. National Coverage Determination (NCD) for Percutaneous Transluminal Angioplasty (PTA) (20.7). www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=201&amp;ncdver=9&amp;bc=BAABAAAAAAAA&amp; (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid services. MLN Matters&reg; Number: SE1119 Revised file://www.cms.gov/MLNMattersArticles/downloads/SE1119.pdf.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1113 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16922=[""].join("\n");
var outline_f16_33_16922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAROTID ENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endarterectomy trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - VA trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - ACAS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - ACST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Delay to benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perioperative complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factors influencing benefit and risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Asymptomatic embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H371860508\">",
"      - Carotid plaque morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Contralateral carotid stenosis or occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Stroke heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Unheralded carotid stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Degree of stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CAROTID STENTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stenting trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - CREST",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - SAPPHIRE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Stenting in specific subgroups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10308274\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PRACTICE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1113|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/50/24366\" title=\"figure 1\">",
"      Endarterectomy asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/30/21998\" title=\"figure 2\">",
"      Endarterectomy stroke ACAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/23/34173\" title=\"figure 3\">",
"      ACST any stroke death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/25/30109\" title=\"figure 4\">",
"      ACST fatal disabling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/50/17197\" title=\"figure 5\">",
"      NASCET endarterectomy stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/58/17325\" title=\"figure 6\">",
"      NASCET endarterectomy stroke death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/37/10846\" title=\"figure 7\">",
"      Meta-analysis of ACAS and ACST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/42/33453\" title=\"figure 8\">",
"      Stroke with carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/35/35389\" title=\"figure 9\">",
"      ACST use of medical treatments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=related_link\">",
"      Carotid artery stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=related_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_33_16923="Factors accuracy exercise test";
var content_f16_33_16923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determinants of sensitivity and specificity in exercise ECG testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Patient characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prior myocardial infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal rest ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Degree of coronary stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extent of coronary stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gender",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Intraobserver variability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ECG interpretation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Angiographic interpretation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Exercise protocol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exercise end points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patient position",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exercise lead system",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ECG criteria for positivity",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16923=[""].join("\n");
var outline_f16_33_16923=null;
var title_f16_33_16924="Adult screening effective doses";
var content_f16_33_16924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult screening effective doses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average effective dose (mSv)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of chest x-rays (PA/lateral) with equivalent radiation dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dual x-ray absorpitometry (DEXA)",
"       </td>",
"       <td>",
"        Conventional radiography",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dual x-ray absorpitometry with CT",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mammogram (2 views)",
"       </td>",
"       <td>",
"        Conventional radiography",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT coronary calcium score",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT colonography (virtual colonoscopy)",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole body screening CT",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        120",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * PA and lateral chest radiograph = .1 mSv.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254.",
"       </li>",
"       <li>",
"        Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078.",
"       </li>",
"       <li>",
"        Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968.",
"       </li>",
"       <li>",
"        Diederich, S, Lenzen, H. Radiation exposure associated with imaging of the chest: comparison of different radiographic and computed tomography techniques. Cancer 2000; 89:2457.",
"       </li>",
"       <li>",
"        Brenner, DJ, Elliston, CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004; 232:735.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16924=[""].join("\n");
var outline_f16_33_16924=null;
var title_f16_33_16925="Neurologic complications of cardiac surgery";
var content_f16_33_16925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic complications of cardiac operations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preventive measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Brachial plexus",
"injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        2-15%",
"       </td>",
"       <td>",
"        Minimize sternal retraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Attention to patient position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Padding arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"17\">",
"        Stroke",
"       </td>",
"       <td colspan=\"1\" rowspan=\"17\">",
"        0.4-6%",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Conduct of cardiopulmonary bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Minimize duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alpha-stat pH management (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Minimally invasive procedures (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid perioperative hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Preoperative screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If significant carotid stenosis",
"consider:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Preoperative stent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Combined CEA/CABG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Avoidance of emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        De-airing maneuvers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Minimize aortic trauma in",
"patients with severely calcified aortas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        TEE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EEG/EP (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        TCD (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Ophthalmologic",
"       </td>",
"       <td>",
"        Clinical 0.1-25%",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Same as stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiography 100%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        Delirium",
"       </td>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        3-32%",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Minimize:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sensory deprivation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benzodiazepine/narcotic use",
"postoperatively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disruption of sleep-wake cycles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Watch for metabolic encephalopathies;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Watch for withdrawal syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subtle neuropsychological",
"       </td>",
"       <td>",
"        10-79%",
"       </td>",
"       <td>",
"        Same as stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"       <td>",
"        &lt;0.1%",
"       </td>",
"       <td>",
"        Wait 2-4 weeks after new stroke before surgery if",
"possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        Seizures",
"       </td>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        0.6%",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Avoid:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyponatremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypocalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Avoid withdrawal of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Avoid toxic doses of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lidocaine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CEA: carotid endarterectomy; EEG: electroencephalography; CABG: coronary artery bypass grafting; EP: evoked potentials; TEE: transesophageal echocardiography; TCD: transcranial Doppler.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16925=[""].join("\n");
var outline_f16_33_16925=null;
var title_f16_33_16926="Breast cancer with tamoxifen";
var content_f16_33_16926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Cumulative rates per 1000 women of invasive and noninvasive breast cancer in NSABP P-1 participants by treatment group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fisher B, Costantino JP, Lawrence D, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P- 1 study. JNCI 2005; 97:1652. Copyright &copy; 2005 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16926=[""].join("\n");
var outline_f16_33_16926=null;
var title_f16_33_16927="PAS stain of BAL fluid in alveolar proteinosis";
var content_f16_33_16927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PAS stain of BAL fluid in pulmonary alveolar proteinosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cytocentrifuged bronchoalveolar lavage specimen stained with PAS shows large amounts of proteinaceous material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_33_16927=[""].join("\n");
var outline_f16_33_16927=null;
